

Genetics meets Environment



4	Welcome Address
6	President & Committees
7	Daily Overview
16	Detailed Programme
43	Invited Speakers
47	Specials & New Formats
57	Networking Programme
61	General Information
71	Freiburg
73	Sponsor Section

Dear colleagues,
welcome to the SSIEM 2022
conference in Freiburg.
Let's meet to discuss the
following topics:



Ute Spiekerkötter
Symposium President

ENVIRONMENT MEETS METABOLISM_ How do environmental factors influence health and disease, what role does the microbiome play and shouldn't we prescribe exercise in metabolic patients?

TECHNOLOGY MEETS METABOLISM_ Single cell RNA sequencing, mechanistic modelling of human metabolism and the hot topics of big data and artificial intelligence in medicine will be addressed.

ETHICS MEETS GENETICS_ The opportunities and challenges as well as the ethical aspects of whole genome screening will be explored. A lifetime's knowledge at birth? What do we actually want to know? A plenary discussion with all speakers will end the session.

REALITY MEETS GENETICS_ In this session, we want to measure what matters to rare disease patients and will focus on academia-driven medicine developments as well as on challenges and opportunities for social entrepreneurs. Sophie Hauenherm will introduce with a dance into the topic: Behind human understanding!

METABOLISM MEETS GENETICS_ We will explore how genetics changed the face of mitochondrial disease and want to understand variant pathogenicity using multi-omic pipelines. Metabolism is also influenced by the epigenetic clock, a new approach.

EPIGENETICS MEETS GENETICS_ We will learn about clinical epigenomics in metabolic diseases. Is epigenetics the 3rd dimension of phenotypic variation and disease risk? In addition a human Mendelian disorder of the DNA demethylation machinery will be introduced to us.

With all of these exciting sessions I am looking forward to meeting all of you in Freiburg!

Kind regards
Ute Spiekerkötter

SCIENTIFIC PROGRAMME

PRESIDENT & COMMITTEES



Symposium President



Ute Spiekerkötter
*University Hospital of Freiburg
Freiburg, Germany*

Local Organising Committee



Ute Spiekerkötter – President
Freiburg, Germany

Sarah Grünert
Freiburg, Germany

Luciana Hannibal
Freiburg, Germany

Anke Schumann
Freiburg, Germany

International Scientific Committee



Kaustuv Bhattacharya
Sydney, Australia



Matthias Baumgartner
Zurich, Switzerland



Jim Bonham
Sheffield, UK



John Christodoulou
Parkville, Australia



Roberto Giugliani
Rio Grande do Sul, Brazil



Johannes Häberle
Zurich, Switzerland



Johan van Hove
Aurora, United States



Anita Inwood
Brisbane, Australia



Stefan Kölker
Heidelberg, Germany



Helen Michelakakis
Athens, Greece



Eva Morava
Rochester, USA



Kimitoshi Nakamura
Kumamoto, Japan



Katrin Ounap
Tartu, Estonia



Dulce Quelhas
Porto, Portugal



David Rosenblatt
Quebec, Canada



Gajja Salomons
Amsterdam, Netherlands



Manuel Schiff
Paris, France

HOTEL STADT FREIBURG

13:00 – 19:00
FAO Guideline Meeting Part I
(by invitation only)

HOTEL STADT FREIBURG	
	7:30
	8:00
	8:30
09:00 – 13:00	9:00
FAO Guideline Meeting Part II <i>(by invitation only)</i>	9:30
	10:00
	10:30
	11:00
	11:30
	12:00
	12:30
	13:00
	13:30
	14:00
	14:30
	15:00
15:30 – 21:30	15:30
INFORM Meeting Part I <i>(registration at INFORM – limited places)</i>	16:00
	16:30
	17:00
	17:30
	18:00
	18:30
	19:00
	19:30
	20:00
	20:30
	21:00
	21:30
	22:00
	22:30
	23:00
	23:30

Side & Administrative Meetings

Please note: This is a programme, which is subject to change without prior notice. For updated information please visit: www.ssiem2022.org

SSIEM 2022 | 7

	JERUSALEM	KYOTO 1	KYOTO 2	KYOTO 3	KYOTO 4	LONDON
7:30						
8:00						
8:30						
9:00						
9:30						
10:00						
10:30						
11:00						
11:30						
12:00	12:00 – 16:00	12:00 – 14:00				
12:30	Annual Meeting of the DGMet	NBS Collaboration Meeting – MetabERN/ISNS/SSIEM <i>(by invitation only)</i>				
13:00						
13:30						
14:00						14:00 – 16:30
14:30					MetabERN Meeting <i>(by invitation only)</i>	
15:00						
15:30						
16:00						16:00 – 18:00
16:30	16:30 – 19:30		16:30 – 19:30	16:30 – 19:30	16:30 – 19:30	SSIEM Council Meeting <i>(council members only)</i>
17:00	MetabERN SNW Amino and Organic acids-related Disorders – AOA <i>(by invitation only)</i>		MetabERN SNW Disorders – PD <i>(by invitation only)</i>	MetabERN SNW Carbohydrate, Fatty Acid Oxidation and Ketone Bodies Disorders – C-FAO <i>(by invitation only)</i>	MetabERN SNW Lysosomal Storage Disorders – LSD <i>(by invitation only)</i>	
17:30						
18:00		18:00 – 19:30				
18:30		MetabERN SNW PM-MD <i>(by invitation only)</i>				
19:00						
19:30						
20:00						
20:30						
21:00						
21:30						
22:00						
22:30						
23:00						
23:30						

MEETING ROOM 1	MEETING ROOM 4	MEETING ROOM 5	HOTEL STADT FRBG	
			07:30 – 21:00	7:30
			INFORM Meeting Part II	8:00
			<i>(registration at INFORM – limited places)</i>	8:30
				9:00
				9:30
				10:00
				10:30
				11:00
11:00 – 13:45				11:30
Annual E-IMD Members Meeting				12:00
<i>(by invitation only)</i>				12:30
				13:00
				13:30
				14:00
				14:30
				15:00
				15:30
				16:00
				16:30
	16:30 – 19:30	16:30 – 19:30		17:00
	MetabERN SNW Congenital Disorders of Glycosylation and Disorders of Intracellular Trafficking – CDG	MetabERN SNW Disorders of Neuromodulators and Other Small Molecules – NOMS		17:30
	<i>(by invitation only)</i>	<i>(by invitation only)</i>		18:00
18:00 – 22:00				18:30
ERNDIM Board of Trustees Meeting				19:00
<i>(by invitation only)</i>				19:30
				20:00
				20:30
				21:00
				21:30
				22:00
				22:30
				23:00
				23:30

	Freiburg	Jerusalem	Porto	Kyoto 1	Kyoto 2	Kyoto 3
7:30						
8:00						
8:30						
9:00	09:00 – 12:00	09:00 – 10:30	09:00 – 12:30	09:00 – 10:30	09:00 – 10:30	09:00 – 10:30
9:30	SSIEM Adult Group Meeting <i>(open to all participants)</i>	ERNDIM Workshop: DPT Netherlands <i>(by invitation only)</i>	Nutrition and Dietetic Session <i>(open to all participants)</i>	ERNDIM Workshop: DPT Czech Republic <i>(by invitation only)</i>	ERNDIM Workshop: DPT Switzerland <i>(by invitation only)</i>	ERNDIM Workshop: DPT France <i>(by invitation only)</i>
10:00						
10:30						
11:00		11:00 – 12:30				
11:30		ERNDIM Workshop <i>(open to all participants)</i>				
12:00				12:00 – 13:30		
12:30				EHOD Members Meeting <i>(by invitation only)</i>		
13:00	12:45 – 13:45	12:45 – 13:45	12:45 – 13:45		12:45 – 13:45	
13:30	Satellite Symposia	Satellite Symposia	Satellite Symposia		SSIEM Adult Group Business Meeting <i>(for all members involved in adult metabolic medicine)</i>	
14:00	14:00 – 14:40					
14:30	Opening Ceremony					
15:00	14:40 – 15:45					
15:30	Environment meets Metabolism					
16:00						
16:30	16:15 – 18:00					
17:00	Technology meets Metabolism					
17:30						
18:00	18:00 – 18:30					
18:30	Garrod Award Lecture					
18:30						
19:00						
19:30						
20:00						
20:30						
21:00						
21:30						
22:00						
22:30						
23:00						

KYOTO 4	LONDON	MEETING ROOM 1	MEETING ROOM 4	MEETING ROOM 5	MEETING ROOM 6	
						7:30
						8:00
						8:30
09:00 – 10:30 ERNDIM Workshop: DPT UK <i>(by invitation only)</i>	09:00 – 10:30 ERNDIM Workshop: NCSF participants' meeting <i>(NCSF participants only)</i>	09:00 – 12:00 GalNet Symposium <i>(by invitation only)</i>		09:00 – 11:00 EHOD Executive Board Meeting <i>(by invitation only)</i>	09:00 – 12:00 JIMD and JIMD Reports – Editorial Meeting <i>(by invitation only)</i>	9:00
			10:00 – 12:00 ETAC Meeting <i>(by invitation only)</i>			9:30
						10:00
						10:30
						11:00
						11:30
						12:00
						12:30
						13:00
						13:30
						14:00
						14:30
						15:00
						15:30
						16:00
						16:30
						17:00
						17:30
						18:00
						18:30
						19:00
						19:30
						20:00
						20:30
						21:00
						21:30
						22:00
						22:30
						23:00
						23:30



	FREIBURG	JERUSALEM	PORTO	KYOTO	LONDON	MEETING ROOM 1
7:30		07:30 – 08:30	07:30 – 08:30	07:30 – 08:30	07:30 – 08:30	07:30 – 08:30
8:00		Satellite Symposia	Satellite Symposia	Satellite Symposia	IOC Meeting	Speed Mentoring
8:30						
9:00	08:45 – 10:15	08:45 – 10:15	08:45 – 10:15	08:45 – 10:45	08:45 – 10:15	
9:30	New Therapies in Lysosomal Disorders	Organic Acidurias	Glycosylation and Carbohydrate Disorders	SSIEM Nurses Meeting <i>(open to all participants)</i>	Patient Representative Meeting	
10:00						
10:30						
11:00	10:45 – 12:45		10:45 – 12:45			
11:30	Ethics meets Genetics		SSIEM-DG Meeting <i>(open to all participants)</i>			
12:00						
12:30						
13:00		13:00 – 13:30	12:45 – 13:15			
		SSIEM Advisory & Council Members Meeting <i>(only SSIEM Advisory Council & Council Members)</i>	SSIEM-DG Executive Committee Meeting <i>(by invitation only)</i>			
13:30		13:30 – 14:30				
14:00		SSIEM Annual General Assembly <i>(only SSIEM Members)</i>				
14:30						
15:00	14:45 – 16:15	14:45 – 16:15	14:45 – 16:15	14:45 – 16:15		
15:30	Mechanisms and Markers in Lysosomal Disorders	New Perspectives in Phenylketouria	Disorders of Fat Metabolism	Novel Diagnostic Technologies		
16:00						
16:30						
17:00	16:45 – 18:35					
17:30	Reality meets Metabolism					
18:00						
18:30						
19:00		18:45 – 19:45	18:45 – 20:15			
19:30		Satellite Symposia	Satellite Symposia			
20:00						
20:30						
21:00						
21:30						
22:00						
22:30						



	SCIENTIFIC THEATRE	POSTER EXHIBITION	CITY CENTRE
7:30		07:30 – 20:15	
8:00		Poster & e-Poster	
8:30			
9:00			
9:30			
10:00			
10:30			
11:00			
11:30			
12:00			
12:30			
13:00	13:00 – 13:45 The Needs of Patients		
13:30			
14:00			
14:30			
15:00			
15:30			
16:00			
16:30			
17:00			
17:30			
18:00			
18:30			
19:00	18:45 – 20:15 Presentation of high ranked posters	18:45 – 20:15 Poster Walk	
19:30			
20:00			
20:30			20:30 – 00:00 Young SSIEM Evening
21:00			
21:30			
22:00			
22:30			

	Freiburg	Jersualem	Porto	Kyoto	Meeting Room 1	Gallery Room 1
7:30		07:30 – 08:30	07:30 – 08:30	07:30 – 08:30	07:30 – 08:30	
8:00		Satellite Symposia	Satellite Symposia	Satellite Symposia	Speed Mentoring	
8:30						
9:00	08:45 – 10:30					
9:30	Metabolism meets Genetics					
10:00						
10:30						10:30 – 11:00 Coffee with the JIMD Editors
11:00	11:00 – 12:30	11:00 – 12:30	11:00 – 12:30	11:00 – 12:30		
11:30	Gene Therapy Clinical Trials	Urea Cycle Disorders	Mitochondrial Disorders	Disorders of Vitamins and Cofactors		
12:00						
12:30					12:30 – 14:30	12:30 – 14:00
13:00	12:45 – 13:45	12:45 – 13:45	12:45 – 13:45	12:45 – 13:45	JIMD and JIMD Reports – Editorial Meeting <i>(by invitation only)</i>	Alumni Café
13:30	Satellite Symposia	Satellite Symposia	Satellite Symposia	Satellite Symposia		
14:00	14:00 – 15:30	14:00 – 15:30	14:00 – 15:30	14:00 – 15:30		
14:30	Gene and innovative Therapies	Amino Acid Disorders	Neurometabolic Disorders	Novel Disease Insights		
15:00						
15:30						
16:00						
16:30						
17:00						
17:30						
18:00						
18:30						
19:00						
19:30						
20:00						
20:30						
21:00						
21:30						
22:00						
22:30						
23:00						

	SCIENTIFIC THEATRE	POSTER EXHIBITION
7:30		07:30-15:30
8:00		Poster & e-Poster
8:30		
9:00		
9:30		
10:00		
10:30		
11:00		
11:30		
12:00		
12:30		
13:00	12:45 – 13:00 Science Slam	
13:30		
14:00		
14:30		
15:00		
15:30	FOYER	
16:00	15:30 – 18:30 Networking Activities	
16:30		
17:00		
17:30		
18:00		
18:30		
19:00		
19:30		KONZERTHAUS
20:00		19:30 – 00:00 Networking Evening with Dinner Speech
20:30		
21:00		
21:30		
22:00		
22:30		
23:00		
23:30		

	FREIBURG	MEETING ROOM 1	POSTER EXHIBITION	
		07:30 – 08:30 Speed Mentoring	07:30-13:15 Poster & e-Poster	7:30
				8:00
				8:30
	08:45 – 10:30 Epigenetics meets Genetics			9:00
				9:30
				10:00
				10:30
				11:00
	11:00 – 11:45 Komrower Lecture			11:30
	11:45 – 12:45 Special Awards Session			12:00
	12:45 – 13:15 Awards			13:00
				14:00
				14:30
				15:00
				15:30
				16:00
				16:30
				17:00
				17:30
				18:00
				18:30
				19:00
				19:30
				20:00
				20:30
				21:00
				21:30
				22:00
				22:30

15:30 – 21:30 | INFORM Meeting Part I (*registration at INFORM – limited places*)

Hotel Stadt Freiburg | Side & Administrative Meetings

International Network for Fatty Acid Oxidation Research and Management

Moderation: Vockley, Jerry (Pittsburgh, USA)

15:30 **Registration**

16:30 **Welcome** | Vockley, Jerry (Pittsburgh, USA)

16:45 **»Philosophical«: What have we learned, what can we expect for the future**

Vianey-Saban, Christine (Lyon, France)

17:45 **Research Discussion**

18:15 | **Break**

19:00 **Networking Reception & Poster Presentation**

PROGRAMME | **MONDAY** | 29 AUGUST 2022

07:30 – 21:00 | INFORM Meeting Part II (*registration at INFORM – limited places*)

Hotel Stadt Freiburg | Side & Administrative Meetings

International Network for Fatty Acid Oxidation Research and Management

Moderation: Vockley, Jerry (Pittsburgh, USA)

07:30 **Registration**

08:30 **Confirmatory Genetic Analysis, when is a positive screen a diagnosis**

Vockley, Jerry (Pittsburgh, USA)

09:00 **Initiation of Treatment / Pre-symptomatic Treatment**

Burton, Barbara (Chicago, USA)

09:30 **Junior Investigator Presentation**

09:45 **Junior Investigator Presentation**

10:00 | **Break**

10:30 **Key nutrition principles for management of FAOD** | *Singh, Rani (Atlanta, USA)*

11:00 **Data on energy balance and calculating total energy needs in subjects with FAODs using the C7 data** | *Gillingham, Melanie (Portland, USA)*

11:30 **Junior Investigator Presentation**

11:45 **Junior Investigator Presentation**

12:00 **Panel Discussion**

12:30	Lunch / Announce Poster Winners; MitoAction & INFORM Family Luncheon; Patient and Family Discussion <i>Spiekerkötter, Ute (Freiburg, Germany) & Vockley, Jerry (Pittsburgh, USA)</i>
14:00	Update on Cardiomyopathy in FOADs <i>Chatfield, Kathryn C. (Aurora, USA)</i>
14:30	Cardiolipin Metabolism and the Heart <i>Ruohola-Baker, Hannele (Seattle, USA)</i>
15:00	Junior Investigator Presentation
15:15	Junior Investigator Presentation
15:30	Break
15:45	Life with a child affected by a fatty acid oxidation defect: Impact on different areas of life, psychological aspects and coping strategies <i>Grünert, Sarah (Freiburg, Germany) & Thiel, Maren (Berlin, Germany)</i>
16:15	Natural History of Retinopathy / LCHAD and the Eye <i>Pennesi, Mark (Portland, USA)</i>
16:45	Case study of Physical Therapy for LCHAD deficiency <i>Tucker, Pamela (Syracuse, USA)</i>
17:00	Junior Investigator Presentation
17:15	Panel Discussion / Summary & Closing remarks
17:45	Break
18:00	INFORM Committee Meeting
19:00	Break
19:30	INFORM Night out in Freiburg



Hans-Albert Stechl

Lukewarm Beef Asparagus Salad

This salad is a main course. At least when you do not just eat a piece of baguette with it, but a nice portion of roast potatoes.

If you cook the brisket with the bones, two bay leaves, a carrot, a piece of leek, half a bunch of parsley, a piece of celeriac, an onion, a clove of garlic and a heaped teaspoon of peppercorn, the most welcome by-product is 2 litres of the finest meat broth. The cooking time for the meat is about 2 hours. The water should not boil wildly, but simmer gently. Use a pointed fork to determine whether the meat is cooked. If the fork penetrates the meat easily, it is done. The old question of whether to put the meat in cold or hot water can be quickly settled: If you want the meat to be as rich as possible, put it in cold water. In

this case, the meat will be leached out a little better when the water is heated slowly. If the focus is on a piece of meat that is as juicy as possible, put it in boiling water.

We combine both cooking methods: Put the bones and all the other ingredients into cold water. Place the meat into the pot as soon as the water boils. Once cooked, cut the meat into small thin slices, put it in a pot and cover it with broth. This prevents it from drying out. Heat it again in the broth shortly before serving.

Asparagus. We recommend asparagus tips or broken asparagus, because they will be cut into pieces anyway. Cook the asparagus until tender to the bite. Clean the baby carrots and likewise cook them until al dente. If a little of the green remains on the carrots, it does not affect the taste, and it looks nice. Cook the sugar snap peas in boiling water for 2 minutes and then rinse with cold running water. Peel the red onion and cut into very fine strips. Clean the radishes and slice them not too thinly. For the herb vinaigrette, mix the mustard, vinegar, meat stock, salt, pepper and sugar until the mustard has dissolved, then add the oil. Chop the parsley, chives and lovage finely and stir into the vinaigrette. Heat the meat in the stock, strain through a sieve, mix loosely with all the ingredients and the vinaigrette and arrange on a platter.

Ingredients (for 4 servings)

1 kg lightly marbled brisket of beef
 1 handful of beef bones
 2 bay leaves
 1 carrot
 ½ leek
 1 small piece of celeriac
 ½ bunch parsley
 1 small onion
 1 clove of garlic
 1 heaped teaspoon peppercorns

 500 g asparagus tips or broken asparagus
 ½ bunch carrots (baby carrots)
 100 g sugar snap peas
 1 small red onion
 ½ bunch radishes

Vinaigrette

1 heaped teaspoon hot mustard
 3 tablespoons vinegar
 3 teaspoons meat stock
 salt and pepper
 1 pinch of sugar
 5 tablespoons olive oil
 ½ bunch parsley
 ½ bunch chives
 ½ bunch lovage

For more recipes please visit: www.freiburger-marktkalender.de

09:00 – 11:00 | SSIEM Adult Group Meeting (*open to all participants*)

Freiburg | Side & Administrative Meetings

Update on porphyria

Moderation: Mochel, Fanny (Paris, France)

09:00 **Introduction and welcome**

09:05 **Interference RNA treatment for acute porphyria**

Sardh, Eliane (Stockholm, Sweden)

09:35 **Treatment of erythropoietic protoporphyria** | *Langendonk, Janneke*

(Rotterdam, Netherlands)

10:05 **Liver complications in porphyrias** | *Ventura, Paolo (Modena, Italy)*

10:35 **Concluding remarks**

10:45 | **Break**

11:00 **Epidemiological Trends and Outcomes of Children, Adolescents, and Adults Hospitalized with Inherited Metabolic disorders : A Population Based Cohort Study** | *Hauser, Stephanie (Aarau, Switzerland)*

11:15 **Plasma globotriaosylsphingosine correlates strongly with disease severity in untreated Fabry disease patients: A tool to aid clinical decision making** | *van der Veen, Sanne (Amsterdam, Netherlands)*

11:30 **Effects of high versus low Phe intake on neurocognitive functioning and wellbeing in adults with PKU; The Phe eat or diet study** | *Wagenmakers, Margreet (Rotterdam, Netherlands)*

11:45 **Alpha-mannosidosis diagnosed in a 47-year-old male: the importance of re-visiting undiagnosed patients** | *Nurse, James (Southampton, UK)*

09:00 – 12:30 | Nutrition and Dietetic Session (*open to all participants*)

Porto | Side & Administrative Meetings

Moderation: Dianin, Alice (Verona, Italy), Lang, Frauke (Mainz, Germany)

09:00 **The gut microbiome in inherited metabolic disorders: the influence of the diet** | *Timmer, Corrie (Amsterdam, Netherlands)*

09:30 **The changing face of PKU - the challenges of nutrition and dietetics in the era of new treatment approaches** | *Rohde, Carmen (Leipzig, Germany)*

10:00 **Overcoming nutritional problems in IEM post-transplant** | *Pedro, Temitope (Stanford, USA)*

10:30 | **Break**

- 10:45 **Efficacy and safety of empagliflozin in glycogen storage disease type Ib** | Grünert, Sarah (Freiburg, Germany)
- 11:15 **Pregnancies in phenylketonuria** | Lier, Dinah (Reutlingen, Germany)
- 11:30 **Pregnancies in other inborn errors of metabolism** | Green, Diane (Salford, UK)

11:00 – 12:30 | ERNDIM Workshop (open to all participants)

Jerusalem | Side & Administrative Meetings

Moderation: Artuch, Rafael (Esplugues de Llobregat, Spain)

- 11:00 **Chair's Update** | Artuch, Rafael (Esplugues de Llobregat, Spain)
- 11:10 **Common DPT sample** | Croft, Joanne (Sheffield, UK)
- 11:20 **Biomarkers for neurotransmitter diseases** | Heales, Simon (London, UK)
- 11:50 **Biomarkers for mitochondrial diseases** | Horvath, Rita (Cambridge, UK)
- 12:20 **Open discussion: Future directions** | Artuch, Rafael (Esplugues de Llobregat, Spain)

14:00 – 14:40 | Opening Ceremony

Freiburg | Opening

- 14:00 **Eroica** | Children
- 14:08 **Welcome Speech** | Spiekerkötter, Ute (Freiburg, Germany)
- 14:23 **Everyone** | Matrix
- 14:30 **The power of humanity** | Matrix and Children

14:40 – 15:45 | Environment meets Metabolism

Freiburg | Plenary Session 1

Chairs: Bhattacharya, Kaustuv (Sydney, Australia), Kölker, Stefan (Heidelberg, Germany)

- 14:40 **Introduction into the session** | Grünert, Sarah (Freiburg, Germany)
- 14:45 **Genetics and the microbiome** | Ley, Ruth (Tübingen, Germany)
- 15:15 **Exercise testing and prescription in metabolic diseases** | Broderick, Carolyn (Sydney, Australia)

15:45 – 16:15 | **Coffee Break**

16:15 – 18:00 | Technology meets Metabolism

Freiburg | Plenary Session 2

Chairs: Michelakakis, Helen (Athens, Greece), Van Hove, Johan (Aurora, USA)

16:15 **Introduction into the session** | *Schuman, Anke (Freiburg, Germany)*

16:25 **Single cell RNA sequencing: understanding liver cell differentiation and plasticity in health and disease** | *Heikenwälder, Mathias (Heidelberg, Germany)*

16:55 **Mechanistic modeling of human metabolism: monogenic and polygenic disorders** | *Fleming, Ronan M.T. (Galway, Ireland)*

17:25 **Big data and artificial intelligence in medicine: the good, the bad and the ugly** | *Lovis, Christian (Genf, Switzerland)*

18:00 – 18:30 | Garrod Award Lecture


Freiburg | Award Lecture

Chair: Rahman, Shamima (London, UK)

18:00 **Delineating the clinical spectrum of isolated methylmalonic acidurias: cbIA and mut** | *Hörster, Friederike (Heidelberg, Germany)*

18:30 – 21:00 | Welcome Reception

Foyer | Networking





Hans-Albert Stechl

Potato, leek and ham quiche

Saying that the served food is made up of leftovers rarely causes a storm of enthusiasm at the table. After all, it still sounds like leftovers.

That's why I prefer to talk about the culinary harmony of food items that are only available in such small quantities that if used individually, do not serve four people. Our fridge had two and a half slices of cooked ham from breakfast of the day before, two leeks, two potatoes, three eggs, half a cup of cream and a well-hardened piece of Parmesan cheese.

Boil the potatoes in their skins until soft, peel and cut into thin slices. Cut off the green parts of the leek that are no longer dewy, as well as the root end. Cut the remaining light-coloured stalk into not too thick

slices. Rinse well in a sieve to remove any residual garden soil. Then steam the slices in a pan with butter over moderate heat for 10 minutes.

Cut the ham into thin slices. Whisk the eggs with the cream, grate the Parmesan, mix with the whisked eggs, salt, pepper and season with nutmeg. Mix the leek with the ham mixture.

Line a 26-centimetre-diameter pan with shortcrust pastry and form a rim about 3 centimetres high. Poke the base several times with a fork.

Cover the base evenly with the potato slices. Sprinkle marjoram - fresh or dried - over the potato slices. Spread the leek and ham mixture evenly over the potato slices. Finally, pour the egg and cream mixture over the top so that everything is nicely moistened. Put the quiche in the oven preheated to 200 degrees (top and bottom heat, middle shelf) and bake for about 40 minutes.

For the shortcrust pastry: If you do not have time, use a ready-made one from a roll. Look carefully - there are salted and sugared ones. However, kneading the shortcrust pastry yourself is anything but rocket science. Knead the flour with your hands (spelt flour works very well here) with room temperature butter cut into pieces, a good pinch of salt and water until you have a smooth dough. Form the dough into a ball, wrap it in kitchen foil and put it in the fridge for 30 minutes. Then roll out a thin dough.

Ingredients *(for 4 servings)*

2-3 slices cooked ham
2 leeks
2 medium potatoes (firm or floury)
3 eggs
½ cup cream
50 g grated parmesan (another leftover hard cheese works as well)
Salt and pepper
Nutmeg
Marjoram
Butter to steam the leeks

Shortcrust pastry

1 roll of pre-made salted pastry or:
200 g spelt flour
100 g room temperature butter
2 tablespoons cold water
1 good pinch of salt
Kitchen foil

For more recipes please visit: www.freiburger-marktkalender.de

08:45 – 10:15 | New Therapies in Lysosomal Disorders

Freiburg | Parallel Session 1A

Chairs: Giugliani, Roberto (Porto Alegre, Brazil), Muschol, Nicole (Hamburg, Germany)

- 08:45 **Retargeting phenylbutyrate, ursodeoxycholic acid, pyrimethamine and betaine for beta-glucocerebrosidase recovery in gaucher disease fibroblasts resulting from homozygous p.L483P mutation** | Kiliç, Ayse (Ankara, Turkey)
- 09:00 **Four-year real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group (ICGG) Gaucher Registry** | Mistry, Pramod (New Haven, USA)
- 09:15 **AZ-3102, a novel brain-penetrant small molecule, significantly improves survival in Sandhoff disease mice** | Walia, Jagdeep (Kingston, Canada)
- 09:30 **The first successful in utero enzyme replacement therapy treatment of a child with CRIM negative infantile-onset Pompe disease** | Cohen, Jennifer L. (Durham, USA)
- 09:45 **Interim 73-week cohorts A, B, and C results of a Ph1/2 study of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II** | Muenzer, Joseph (Chapel Hill, USA)
- 10:00 **RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from a Phase 1/2 study** | Giugliani, Roberto (Porto Alegre, Brazil)

08:45 – 10:15 | Organic Acidurias

Jerusalem | Parallel Session 1B

Chairs: Mühlhausen, Chris (Göttingen, Germany), Scholl-Bürgi, Sabine (Innsbruck, Austria)

- 08:45 **Altered glutamine anaplerosis in MMUT deficiency** | Traversi, Florian (Zurich, Switzerland)
- 09:00 **Different urinary biomarker patterns in a large cohort of patients with classical organic acidurias of branched-chain amino acid metabolism** | Köpfer, Felix (Heidelberg, Germany)
- 09:15 **The liver in methylmalonic and propionic acidemias: are there risk factors for cancer?** | Brassier, Anaïs (Paris, France)
- 09:30 **A network medicine approach identifies key TCA cycle enzymes as potential therapeutic targets in organic acidemias** | Piper, Zina (Hamburg, Germany)
- 09:45 **Cognitive functions are not necessarily spared in early diagnosed individuals with glutaric aciduria type 1 – a national prospective study over 20 years** | Märtner, Eva Marie Charlotte (Heidelberg, Germany)
- 10:00 **Newborn screening and disease variants predict neurological outcome in isovaleric aciduria** | Mütze, Ulrike (Heidelberg, Germany)

08:45 – 10:15 | Glycosylation and Carbohydrate Disorders

Porto | Parallel Session 1C

Chairs: Morava, Eva (Rochester, USA), Santer, Rene (Hamburg, Germany)

- 08:45 **Sodium D,L-3-hydroxybutyrate in the treatment of GLUT1 deficiency syndrome** | Bernhardt, Isaac (Auckland, New Zealand)
- 09:00 **Anaplerotic therapy using Triheptanoin for patients with glycogen storage disease type I (GSD I): clinical trial results** | El-Gharbawy, Areeg (Durham, USA)
- 09:15 **Investigating metabolic adaptations in PMM2-CDG** | Radenkovic, Silvia (Rochester, USA)
- 09:30 **Functional platforms for the characterization of PMM2-CDG clinical variants** | Falquina, Cristina Segovia (Madrid, Spain)
- 09:45 **Oral sialic-acid supplementation in NANS-CDG: Results of a single center, open label, observational pilot study** | van Karnebeek, Clara (Amsterdam, Netherlands)
- 10:00 **Cellular fluxomics to study sugar metabolism in Galactosemia and Congenital Disorders of Glycosylation** | Noga, Marek (Nijmegen, Netherlands)

08:45 – 10:15 | Patient Representative Meeting

London | New Formats

08:45 – 10:45 | SSIEM Nurses Meeting (open to all participants)

Kyoto | Side & Administrative Meetings

Moderation: Inwood, Anita (South Brisbane, Australia)

- 08:45 **Introduction and welcome** | Meyer, Marie-Louise (Freiburg, Germany)
- 09:00 **Comparison of inpatient length of stay (LOS) at a quaternary paediatric hospital** | Dalkeith, Troy (Sydney, Australia)
- 09:20 **Clinical nurse specialist role and transition: The model of care for transition in Manchester and the role of the clinical nurse specialist** | Hutton, Rebekah (Manchester, UK)
- 09:40 **A single metabolic centres experience of continuous glucose monitoring (CGM) for monitoring of hypoglycaemia** | Smith, Katie (Bristol, UK)
- 10:00 **NP/CNC/RN role presentation: The value of clinical nurse specialists and nurse practitioners in a metabolic service** | Annemarie De Vreugd (Nijmegen, Netherlands)
- 10:20 **An 18-month-old female with ornithine transcarbamylase (OTC) deficiency who presented with hyperammonaemia which progressed to acute liver failure** | Inwood, Anita (South Brisbane, Australia)
- 10:40 **Summary and close** | Meyer, Marie-Louise (Freiburg, Germany)

10:15 – 10:45 | Break

10:45 – 12:45 | Ethics meets Genetics

Freiburg | Plenary Session 3

Chairs: Bonham, James Robert (Sheffield, UK), Spiekerkötter, Ute (Freiburg, Germany)

- 10:45 **Introduction into the session** | *Spiekerkötter, Ute (Freiburg, Germany)*
- 10:55 **Newborn screening by whole genome sequencing: opportunities and challenges** | *Bick, David (London, UK)*
- 11:20 **Ethics of big data and whole genome screening: how to make chicken from chicken salad?** | *Krones, Tanja (Zurich, Switzerland)*
- 11:45 **A lifetime's knowledge at birth? What do we actually want to know?**
Hopkins, Henrietta (London, UK)
- 12:10 **Plenary discussion moderated by J. Bonham, U. Spiekerkötter** | *Bick, David (London, UK), Gross, Edith (Paris, France), Hopkins, Henrietta (London, UK), Krones, Tanja (Zurich, Switzerland)*

10:45 – 12:45 | SSIEM-DG Meeting (open to all participants)

Porto | Side & Administrative Meetings

Moderation: Rocha, Júlio César (Lisboa, Portugal)

- 10:45 **Welcome and business meeting**
- 11:15 **Dietary management of homocystinuria (HCU caused by cystathionine beta-synthase deficiency: Perspectives from a global cohort of metabolic dietitians** | *Starin, Danielle (Washington, USA)*
- 11:30 **A three-year longitudinal study comparing bone mass, density and geometry measured by DXA, pQCT and bone turnover markers in children with PKU taking either L amino acid or glycomacropeptide protein substitutes** | *Daly, Anne (Birmingham, UK)*
- 11:45 **Normalization of intact protein intake among adults with phenylketonuria after sustained Pegvaliase treatment** | *Singh, Rani (Atlanta, USA)*
- 12:00 **Anita MacDonald lecture: What can we expect from nutrition in the next decade?** | *Singh, Rani (Atlanta, USA)*
- 12:30 **Conclusion**

12:45 – 14:45 | Lunch & Poster Viewing

13:00 – 13:45 | The Needs of Patients

Scientific Theatre | New Formats

13:00 – 13:30 | SSIEM Advisory & Council Members Meeting

Jerusalem | Side & Administrative Meetings (only SSIEM Advisory Council & Council Members)

13:30 – 14:30 | SSIEM Annual General Meeting

Jerusalem | Side & Administrative Meetings (only SSIEM Members)

14:45 – 16:15 | Mechanisms and Markers in Lysosomal Disorders

Freiburg | Parallel Session 2A

Chairs: Eyskens, Francois (Antwerp, Belgium), Van der Ploeg, Ans (Rotterdam, Netherlands)

- 14:45 **Lyso-Gb3 elicits a proteotoxic effect on a neuronal cell model**
Heywood, Wendy (London, UK)
- 15:00 **Next-generation deep plasma proteomics reveals systemic and tissue-specific remodeling in Fabry Disease** | Bekri, Soumeia (Rouen, France)
- 15:15 **Quantitative nuclear magnetic resonance spectroscopy-based metabolomics of urine samples in metachromatic leukodystrophy: identifying indicators for neurodegeneration and disease progression** | Laugwitz, Lucia (Tübingen, Germany)
- 15:30 **LC-MSMS sulfatides measurement in dried blood spots for the diagnosis of metachromatic leukodystrophy** | Pettazzoni, Magali (Bron, France)
- 15:45 **Neurofilament light as a biomarker for involvement of the brain in classic infantile Pompe patients** | Mackenbach, Maarten (Rotterdam, Netherlands)
- 16:00 **Bi-allelic variants in VPS16, encoding a subunit of HOPS/CORVET complexes, cause a mucopolysaccharidosis-like disease** | Cayuela, Jorge Asin (Gothenburg, Sweden)

14:45 – 16:15 | New Perspectives in Phenylketonuria

Jerusalem | Parallel Session 2B

Chairs: Hennermann, Julia B. (Mainz, Germany), Karall, Daniela (Innsbruck, Austria)

- 14:45 **Characterization of a humanized PKU mouse carrying the frequent splicing variant c.1066-11G>A** | Desviat, Lourdes (Madrid, Spain)
- 15:00 **Cognitive deficits emerge in early-treated adult PAH-deficient mice following discontinuation of pegvaliase therapy** | Harding, Cary O. (Portland, OR, USA)
- 15:15 **Investigation of the phenylalanine hydroxylase proteostasis network reveals potential therapeutic targets for phenylketonuria** | Haupt, Luka Janina (Hamburg, Germany)
- 15:30 **Searching for new potential biomarkers in adults with Phenylketonuria**
van Wegberg, Annemiek (Groningen, Netherlands)
- 15:45 **A long non-coding RNA (lncRNA) transcript HULC regulates phenylalanine hydroxylase activity and could act as a new therapeutical agent in phenylketonuria** | Feillet, François (Nancy, France)
- 16:00 **A CRISPR/Cas9 genome-edited PAH-deficient cell line for studying PKU**
Koppes, Erik (Pittsburgh, USA)

14:45 – 16:15 | Disorders of Fat Metabolism

Porto | Parallel Session 2C

Chairs: Vockley, Jerry (Pittsburgh, USA), Wanders, Ronald (Amsterdam, Netherlands)

- 14:45 **Biochemical studies in fibroblasts to interpret variants of unknown significance in the ABCD1 gene** | Ferdinandusse, Sacha (Amsterdam, Netherlands)
- 15:00 **Upregulation of glycogen cycling with a triheptanoin diet replenishes glycogen stores in very long chain acyl-CoA dehydrogenase deficient mice (VLCAD-/-)** | Nurjanah, Siti (Freiburg, Germany)
- 15:15 **Thermo-sensitive mitochondrial trifunctional protein deficiency presenting with episodic myopathy** | Schwantje, Marit (Utrecht, Netherlands)
- 15:30 **Restoring succinyllysine antigenic signal and improving O2 consumption of CPT II deficient cells treated with anaplerotic compounds** | Seminotti, Bianca (Pittsburgh, USA)
- 15:45 **Plasma metabolomics during anabolic conditions among subjects with a fatty acid oxidation disorder compared to normal controls** | Gillingham, Melanie (Portland, USA)
- 16:00 **Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin-1-deficient patients** | de Lonlay, Pascale (Paris, France)

14:45 – 16:15 | Novel Diagnostic Technologies

Kyoto | Parallel Session 2D

Chairs: Ribes, Antonia (Barcelona, Spain), Vaz, Frederic (Amsterdam, Netherlands)

- 14:45 **Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM-MS for rapid detection of oligosaccharidoses** | Hagemeyer, Marne (Rotterdam, Netherlands)
- 15:00 **Discovery of new plasma biomarkers for Sjögren Larsson syndrome by untargeted lipidomics** | Vaz, Frederic (Amsterdam, Netherlands)
- 15:15 **Unmasking the functional impact of variants of uncertain significance using knock-in cell lines generated by CRISPR/Cas9** | Muñoz-Pujol, Gerard (Barcelona, Spain)
- 15:30 **Liver-on-a-tube: Hollow fiber membrane technology to study liver metabolism and disease** | Lehmann, Vivian (Utrecht, Netherlands)
- 15:45 **Multiplexing complexome profiling to foster routine protein complex profiling in medical research** | Guerrero-Castillo, Sergio (Hamburg, Germany)
- 16:00 **Expanded phenotyping by microscopic imaging** | Roels, Frank (Gent, Belgium)

16:15 – 16:45 | **Coffee Break**

16:45 – 18:35 | Reality meets Metabolism

Freiburg | Plenary Session 4

Chairs: Häberle, Johannes (Zurich, Switzerland), Inwood, Anita (Brisbane, Australia)

- 16:45 **Introduction into the session** | Grünert, Sarah (Freiburg, Germany)
- 16:55 **Sophie Hauenherm – Behind human understanding** | Hauenherm, Sophie (Dresden, Germany)
- 17:05 **Measuring what matters to rare disease patients – patient-reported outcomes** | Huemer, Martina (Bregenz, Austria)
- 17:35 **Academia-driven medicine development: towards new public-private partnerships** | Hollak, Carla (Amsterdam, Netherlands)
- 18:05 **Rare diseases: challenges and opportunities for social entrepreneurs** | Sireau, Nicolas (Cambridge, UK)

18:45 – 20:15 | Poster Walk | Poster Exhibition

18:45 – 20:15 | High ranked Posters

Scientific Theatre | New Formats

20:30 – 00:00 | Young SSIEM Evening

Markthalle | Networking



Hans-Albert Stechl

Grandma's apple pie

This apple pie warms the soul and it keeps us meaningfully busy in the kitchen for 2 hours.

It all starts with a shortcrust pastry: add flour, sugar, salt, water and refrigerator-cold butter cut into small pieces into a bowl. Many swear by margarine instead of butter, not for reasons of economy, but because margarine supposedly makes the dough a touch crumblier. Since tasty premium margarine is available nowadays, this variant is great to use. Knead the ingredients with your hands until everything is smoothly combined. Form the dough into a ball, cover and chill in the refrigerator for 30 minutes. Peel the apples, cut into eighths, and remove the core, place in a bowl and sprinkle generously with lemon

juice. Lay out a piece of baking paper, place the dough ball in the centre, dust with flour and roll out with a rolling pin until you have a round plate with a diameter slightly larger than the diameter of the baking pan. For a 26-centimetre baking pan, the dough layer should measure about 35 centimetres.

Transfer the pastry sheet together with the baking paper into the pie dish and press down on the bottom and sides. Cut away any excess dough on the edges. Cover the base with the apple slices. Brush the apples with melted butter, sprinkle lightly with sugar and cinnamon. Bake for 25 minutes in an oven preheated to 180 degrees Celsius (place the pie crust below the oven's middle shelf, so that the base bakes well).

Icing: Beat the sugar, vanilla sugar and eggs in a bowl with a mixer (whisk inserts). This takes at least five minutes, until the mixture is foamy and takes on a light colour. Melt the butter in a saucepan and add the cream, then heat, but do not bring to a boil. Pour the cream into the foamy sugar and egg mixture while stirring, and then pour the glaze over the apples.

Bake the pie for a further 20 minutes with the last 5 minutes set with bottom heat only.

Take the pie out, sprinkle lightly with sugar and caramelize by returning the pie to the oven with heat set on high.

Ingredients

Shortcrust pastry
250 g flour
125 g butter or margarine
50 g sugar
1 pinch of salt
2 tablespoons cold water

Topping

1 kg crisp apples
Some lemon juice
50 g butter
Cinnamon powder
Sugar

Icing

60 g sugar
1 tablespoon vanilla sugar
2 eggs
30 g butter
200 g cream
Sugar for caramelising

08:45 – 10:30 | Metabolism meets Genetics

Freiburg | Plenary Session 5

Chairs: Freisinger, Peter (Reutlingen, Germany), Ounap, Katrin (Tartu, Estonia)

08:45 **Introduction into the session** | Schumann, Anke (Freiburg, Germany)

08:55 **How genetics changed the face of mitochondrial disease**

Tynnismaa, Henna (Helsinki, Finland)

09:25 **Understanding variant pathogenicity using multi-omic pipelines**

Prokisch, Holger (Neuherberg, Germany)

09:55 **The epigenetic clock and metabolism** | Raj, Kenneth (Cambridge, UK)

10:30 – 11:00 | Coffee with the JIMD Editors

Gallery Meeting Room 1 | New Formats

10:30 – 11:00 | Coffee Break

11:00 – 12:30 | Gene Therapy Clinical Trials

Freiburg | Parallel Session 3A

Chairs: Schulze, Andreas (Toronto, Canada), van Karnebeek, Clara (Amsterdam, Netherlands)

11:00 **Sustained efficacy and safety at week 52 and up to three years in adults with glycogen storage disease type Ia (GSDIa): results from a phase 1/2 clinical trial of DTX401, an AAV8-mediated, liver-directed gene therapy** | Derks, Terry G. (Groningen, Netherlands)

11:15 **Metabolic abnormalities in canavan disease and reduction in CNS N-acetyl-L-aspartate in patients receiving systemic AAV9-mediated ASPA gene transfer** | Eichler, Florian (Boston, MA, USA)

11:30 **RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study** | Wang, Raymond (Orange, USA)

11:45 **AT845 gene replacement therapy for Late Onset Pompe disease: preliminary safety and efficacy data from FORTIS, a phase I/II open-label clinical study** | Manera, Jordi Diaz (Newcastle upon Tyne, UK)

12:00 **Safety and efficacy of DTX301 in adults with late-onset ornithine transcarbamylase (OTC) deficiency: A Phase 1/2 Trial** | Harding, Cary O. (Portland, OR, USA)

12:15 **From academic clinical development to an approved commercial drug administered in multiple highly specialised centres: arsa-cel, a lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy (MLD)** | Fumagalli, Francesca (Milano, Italy)

11:00 – 12:30 | Urea Cycle Disorders

Jerusalem | Parallel Session 4B

Chairs: Huidekoper, Hidde (Rotterdam, Netherlands), Nakamura, Kimitoshi (Kumamoto, Japan)

- 11:00 **Neurometabolic impact of liver transplantation in six patients with argininosuccinate lyase deficiency (ASLD)** | Siri, Barbara (Roma, Italy)
- 11:15 **In vivo lentiviral gene therapy for argininosuccinic aciduria** | Touramanidou, Loukia (London, UK)
- 11:30 **Proof of concept of in vivo mRNA therapy in a mouse model of argininosuccinic aciduria** | Gurung, Sonam (London, UK)
- 11:45 **O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis** | Soria, Leandro R. (Pozzuoli, Italy)
- 12:00 **In vivo assessment of ureagenesis using stable isotope tracing to monitor disease and treatment efficacy** | Poms, Martin (Zurich, Switzerland)
- 12:15 **Severity-adjusted evaluation of newborn screening on the metabolic disease course in cytosolic Urea Cycle Disorders** | Zielonka, Matthias (Heidelberg, Germany)

11:00 – 12:30 | Mitochondrial Disorders

Porto | Parallel Session 3C

Chairs: Christodoulou, John (Melbourne, Australia), Rahman, Shamima (London, UK)

- 11:00 **Discovery and replication of novel biomarkers for mitochondrial diseases in a cohort of 2,000 individuals** | Smirnov, Dmitrii (München, Germany)
- 11:15 **Unlocking the mitochondrial genome for gene therapy and modelling disease** | Koppens, Martijn (Utrecht, Netherlands)
- 11:30 **Reversal of m.3243A>G related defects to advance drug screening »hits« towards clinical trials** | Kozicz, Tamas (Rochester, USA)
- 11:45 **Inborn disorders of the malate aspartate shuttle lead to disturbed NAD⁺/NADH redox balance, glycolysis and defective serine biosynthesis** | Broeks, Melissa (Utrecht, Netherlands)
- 12:00 **Ryanodine receptor type 3 variants cause acute episodes of rhabdomyolysis related to abnormal calcium homeostasis and impaired autophagy** | de Calbiac, Hortense (Paris, France)
- 12:15 **3-methylglutaconic aciduria type II: The molecular mechanism responsible for the mitochondrial dysfunction** | Yoo, Sukdong (Yangsan-Si, South Korea/ROK)

11:00 – 12:30 | Disorders of Vitamins and Cofactors

Kyoto | Parallel Session 3D

Chairs: Hannibal, Luciana (Freiburg, Germany), Schwahn, Bernd (Manchester, UK)

- 11:00 **Oxidative stress and mitochondrial respiration impairment induced by sulfite in rat brain are prevented by the mitochondria-targeted antioxidant XJB-5-131**
Leipnitz, Guilhian (Porto Alegre, Brazil)
- 11:15 **Biochemical investigation of SAM mediated allosteric inhibition of MTHFR**
Blomgren, Linnea (Zurich, Switzerland)
- 11:30 **Influence of early identification and therapy on long-term outcomes in early-onset MTHFR deficiency** | *Yverneau, Mathilde (Rennes, France)*
- 11:45 **Improved biochemical profile after hydroxocobalamin dose-escalation in cobalamin C defect** | *Olivieri, Giorgia (Roma, Italy)*
- 12:00 **Personalized modeling of altered metabolic states inborn errors of cobalamin metabolism** | *Heinken, Almut (Nancy, France)*
- 12:15 **Novel biochemical and clinical evidence reveals abnormal concentrations of acetylated amino acids in cerebrospinal fluid in acetyl-CoA transporter deficiency** | *Sikic, Katarina (Zagreb, Croatia)*

12:30 – 14:00 | Alumni Café

Gallery Meeting Room 1 | New Formats

12:30 – 14:00 | Lunch & Poster Viewing

12:45 – 13:00 | Science Slam: The World of Epigenetics!

Scientific Theatre | New Formats | *Hensel, Kai O. (Wuppertal, Germany)*

14:00 – 15:30 | Gene and innovative Therapies

Freiburg | Parallel Session 4A

Chairs: Anikster, Yair (Tel Hashomer, Israel), Grünewald, Stephanie (London, UK)

- 14:00 **Eladocogene exuparvovec gene therapy improves motor development in patients with aromatic L-amino acid decarboxylase deficiency** | *Hwu, Paul Wuh-Liang (Taipei City, Taiwan)*
- 14:15 **Intracerebral gene therapy in 2 patients with aromatic-L acid decarboxylase (AADC) deficiency** | *Roubertie, Agathe (Montpellier, France)*
- 14:30 **Hematopoietic stem & progenitor cell gene therapy for Hurler syndrome: interim clinical results and extensive metabolic correction** | *Tucci, Francesca (Milano, Italy)*

- 14:45 **Novel gene supplementation, genome editing and cellular therapeutic approaches to treat Glutaric Aciduria Type I** | Bissig, Karl-Dimitter (Durham, USA)
- 15:00 **Sustained efficacy of neonatal AAV gene therapy for maple syrup urine disease in mice** | Pontoizeau, Clément (Paris, France)
- 15:15 **Pegzilarginase efficacy in arginase 1 deficiency: results of the PEACE pivotal phase 3 trial** | Russo, Rossana Sanchez (Atlanta, USA)

14:00 – 15:30 | Amino Acid Disorders

Jerusalem | Parallel Session 3B

Chairs: Knerr, Ina (Dublin, Ireland), Kozich, Viktor (Praha, Czech Republic)

- 14:00 **Efficacy and pharmacokinetics of betaine in CBS and cbIC deficiency: a cross over randomized controlled trial** | Imbard, Apolline (Paris, France)
- 14:15 **Branched chain ketoacid dehydrogenase kinase (BCKDK) deficiency: a treatable neurodevelopmental disease amenable to newborn screening** | Constante, Juliana R. (Barcelona, Spain)
- 14:30 **The impact of liver transplantation on health-related quality of life in intoxication-type inborn errors of metabolism** | Greco, Benedetta (Rome, Italy)
- 14:45 **Nutrigenomics on the fly: a systematic animal model approach to finding dietary treatments for inherited metabolic diseases** | Johnson, Travis (Clayton, Australia)
- 15:00 **Isoleucine to valine substitutions by IARS1 help maintain cellular function during nutritional stress** | Kok, Gautam (Utrecht, Netherlands)
- 15:15 **Genetic correction of ornithine delta-aminotransferase mutation and metabolomic analyses of iPSC lines derived from gyrate atrophy patients** | Hyvonen, Mervi (Helsinki, Finland)

14:00 – 15:30 | Neurometabolic Disorders

Porto | Parallel Session 4C

Chairs: Desviat, Lourdes (Madrid, Spain), Mochel, Fanny (Paris, France)

- 14:00 **Identifying the mechanism by which creatine represses expression of AGAT** | Lee, Alex (Toronto, Canada)
- 14:15 **ASS1 deficiency is associated with impaired neuronal differentiation in zebrafish larvae** | Seidl, Marie J. (Heidelberg, Germany)
- 14:30 **Identification of Cln5 as S-depalmitoylase highlights the significance of reversible protein palmitoylation in childhood dementia and Alzheimer's disease** | Steinfeld, Robert (Zurich, Switzerland)
- 14:45 **Cerebrospinal fluid amino acids glycine, serine, and threonine in nonketotic hyperglycinemia** | Van Hove, Johan (Aurora, CO, USA)
- 15:00 **COX11 defects are a novel cause of an infantile-onset mitochondrial encephalopathy** | Christodoulou, John (Parkville, Australia)
- 15:15 **The time has come for newborn screening for pyridoxine-dependent epilepsy** | Coughlin, Curtis (Aurora, USA)

14:00 – 15:30 | Novel Disease Insights

Kyoto | Parallel Session 1D

Chairs: Mills, Philippa (London, UK), Rutsch, Frank (Muenster, Germany)

- 14:00 **ARSK deficiency – a novel subtype of mucopolysaccharidosis** | *Plecko, Barbara (Graz, Austria)*
- 14:15 **Glutaminase deficiency impairs neuronal function and can be partially rescued with glutamate supplementation** | *Santra, Saikat (Birmingham, UK)*
- 14:30 **A case of 3-MCC leading to the discovery of a novel neurodevelopmental syndrome caused by bi-allelic loss-of-function variants in RABGAP1**
Oh, Rachel (Toronto, Canada)
- 14:45 **Bi-allelic variants in NAE1 cause intellectual disability, ischiopubic hypoplasia, stress-mediated lymphopenia and neurodegeneration** | *Muffels, Irena J. J. (Utrecht, Netherlands)*
- 15:00 **Infantile superoxide dismutase 1 deficiency syndrome (ISODDES) is an infantile-onset motor neuron disease with impaired glutathione metabolism** | *Park, Julien H. (Münster, Germany)*
- 15:15 **A previously undescribed combination of juvenile ALS with crystalline retinopathy caused by a de novo mutation in SPTLC2 causing a shift in substrate specificity of Serine Palmitoyl Transferase towards longer chain acyl-CoA's** | *Verloo, Patrick (Belgium)*

15:30 – 18:30 | Networking Activities

19:30 – 00:00 | Networking Evening with Dinner Speech

Konzerthaus | Networking





Hans-Albert Stechl

Lukewarm pumpkin salad

This pumpkin salad with its autumnal flavour gets its culinary appeal from the combination of oriental spices, the sweetness of dates and the bitter-tart freshness of radicchio.

Cut the pumpkin into quarters and scrape out the fibrous inside with the seeds using a spoon. Depending on the type of pumpkin you choose, you may have to peel the squash. Hokkaido pumpkin can spare you this work. It would be a mistake, however, to focus only on making the work easier and leave out many other tasty pumpkin varieties, such as the butternut (nutty flavour) or the chestnut squash (reminiscent of chestnuts).

Cut the pumpkin into cubes of about 2 centimetres. First marinate the pumpkin cubes. For the marinade, finely grate the ginger, finely

crush the cumin in a mortar and mix together with cinnamon and olive oil.

Put the pumpkin cubes in a bowl, pour the marinade over them, mix everything well and leave to marinate for 15 minutes. Spread on a baking tray and cook in an oven preheated to 200 degrees (top and bottom heat, middle shelf). This takes between 20 and 30 minutes, depending on the type of pumpkin. The pumpkin should be soft yet firm, it should never be overcooked or mushy.

Prepare the couscous according to the instructions on the packet. Loosen the couscous well with a fork.

Pit the dates and cut them into small pieces. Pluck the parsley and chop finely. Wash the radicchio, spin dry and cut or pluck into large pieces. Put together in a large bowl with the pumpkin cubes, which should still be warm, and the couscous.

The vinaigrette consists of olive oil, lemon juice, honey, pepper and, to spice it up, add a pinch of chilli powder. Mix everything well and pour over the salad, mix thoroughly and leave to infuse for a few minutes. Arrange the salad on a platter. Sprinkle with a little coarse salt and coarsely ground pepper and finally sprinkle with the finely chopped parsley.

Toasted white bread goes very well with this dish. You can also cube the bread (sugar cube size), fry it in butter in a pan until golden and then incorporate as croutons into the salad.

Ingredients *(for 4 servings)*

1 pumpkin weighing
approx. 1 kg

Marinade

1 thumb-sized piece of ginger
1 heaped teaspoon ground
Cinnamon
1 heaped teaspoon of ground
Cumin seeds
1 dash olive oil

200 g couscous
1 small head of radicchio
10 dates
½ bunch flat-leaf parsley

Vinaigrette

1 tablespoon honey
4 tablespoons olive oil
1 lemon
Salt and pepper
1 pinch of chilli powder
1-2 baguettes
A little butter

For more recipes please visit: www.freiburger-marktkalender.de

08:45 – 10:30 | Epigenetics meets Genetics

Freiburg | Plenary Session 6

Chairs: Baumgartner, Matthias (Zurich, Switzerland), Quelhas, Dulce (Porto, Portugal)

08:45 **Introduction into the session** | *Spiekerkötter, Ute (Freiburg, Germany)*

08:55 **Clinical epigenomics meets metabolic diseases and environment**
Sadikovic, Bekim (London, Canada)

09:25 **Developmental plasticity: the 3rd dimension of phenotypic variation and disease risk** | *Nadeau, Joseph (Scarborough, USA)*

09:55 **Beck-Fahrner syndrome: Delineation of a human mendelian disorder of the DNA demethylation machinery** | *Fahrner, Jill A. (Baltimore, USA)*

10:30 – 11:00 | **Coffee Break**

11:00 – 11:45 | Komrower Lecture

Freiburg

Chair: Salomons, Gajja (Amsterdam, Netherlands)

11:00 **On pathways and blind alleys** | *Plecko, Barbara (Graz, Austria)*

11:45 – 12:45 | Special Awards Session

Freiburg | Special Awards Session

Chairs: Salomons, Gajja (Amsterdam, Netherlands), Schiff, Manuel (Paris, France)

11:45 **Characterization of the 1,5-anhydroglucitol transporter SGLT5 that was found to be mutated in a G6PC3-deficient child with a mild form of neutropenia**
Veiga-da-Cunha, Maria (Bruxelles, Belgium)

12:00 **Tailored amino acid treatment for mitochondrial ARS and QARS1 deficiencies**
Muffels, Irena J.J. (Utrecht, Netherlands)

12:15 **O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis** | *Soria, Leandro R. (Pozzuoli, Italy)*

12:30 **Deficient protein glycosylation and compromised functional integrity of PMM2 deficient neurons and brain organoids** | *Shah, Rameen (Rochester, USA)*

12:45 – 13:15 | Awards

Freiburg

INVITED SPEAKERS

INVITED SPEAKERS



David Bick
London, UK



Carolyn Broderick
Sydney, Australia



Jill A. Fahrner
Baltimore, USA



Ronan M. T. Fleming
Galway, Ireland



Mathias Heikenwälder
Heidelberg, Germany



Carla Hollak
Amsterdam, Netherlands



Henrietta Hopkins
London, UK



Martina Huemer
Bregenz, Austria



Tanja Krones
Zurich, Switzerland



Ruth Ley
Tübingen, Germany



Christian Lovis
Geneva, Switzerland



Joseph Nadeau
Scarborough, USA



Holger Prokisch
Neuherberg, Germany



Kenneth Raj
Cambridge, UK




Bekim Sadikovic
London, Canada



Nicolas Sireau
Cambridge, UK



Henna Tyynismaa
Helsinki, Finland





SPECIALS & NEW FORMATS



© Tina Plötze and © Ivett Csikós

Community social & health Project — Matrix

Eroica_

Children of the dance class from TV Freiburg-Herdern under the lead of Ivett Csikós have expressed »Eroica«, the 3rd symphony of Ludwig van Beethoven through the form of dance. The name Eroica refers to a heroic symphony and was composed from 1802 to 1803. Today the symphony is considered revolutionary. The children were significantly involved in developing the choreography themselves, in order to foster their independence. Taking responsibility for the whole group and being self-disciplined were of major importance during this project. Everything, starting with the planning and designing this performance was developed under the motto: »Growing together«. Together, the children created something very special, where social background or dancing skills made no difference.

Dancers: Alessa Simon, Caelyn Banks, Jana Schepky, Tim Knochel, Nora Spiekerkötter, Maria Bothe, Leonie Klaus, Anna Breit, Ivett Csikós



Everyone_

The piece is about the »Declaration of human rights« in 1948. To the music of Max Richters "Voices", Matrix highlights that Everyone is responsible for living and fighting for our human rights. We still have a long way to go until these rights are applied to Everyone!

Dancers: Niko Sonner, Pauline Ihme, Nora Spiekerkötter, Maria Bothe, Leonie Klaus, Anna Breit, Ivett Csikós, Jakob Matthaei und Simon Matthaei

The power of humanity — 250 Years Beethoven

Even 250 years after the birth of the »titan« Ludwig van Beethoven, the humanitarian and enlightening ideas of this musical genius are still highly relevant. Beethoven understood the political »fire« of his works. The meaning of the symphony as an expression of the highest form of humanity and the phrase »all men become brothers« is what made the ode a perfect choice for the European anthem. Today, the European anthem stands as a symbol of »unity in diversity«, which is also the fundamental idea of this community dance project called »The Power of Humanity«. The project introduces children, teenagers and young adults from different social backgrounds to classical music. Just as Prometheus brings fire to humankind, Beethoven's music ignites the creative potential of young people. Tolerance, openness and intercultural diversity can be experienced directly in this dance encounter.

Dancers: Niko Sonner, Pauline Ihme, Nora Spiekerkötter, Maria Bothe, Leonie Klaus, Jakob Matthaei, Simon Matthaei and children

Christina Plötze is a dance lecturer at Freiburg University, as well as coach and choreographer of the Showteam Matrix. In 2004 she founded Matrix, which is the official showteam of the German and the Baden Gymnastics Federation. Matrix was 4 times »The Freiburger team of the year«. The team has performed with great success winning three times the gold medal in the world championship of show performances »Gym for Life world challenge«. Matrix represented the German Gymnastics Federation internationally such as in Tokyo, Fiuggi, Seoul, Busan, Dornbirn, Lausanne, Siauliai, Kapstadt, Helsinki, Oslo and Suwon.

Ivett Csikós has been an active member of the Showteam Matrix and Turnverein Freiburg-Herdern, the gymnastics club in the Freiburg district Herdern, since 2011. She is an aerobic trainer and now coaching the dance class for children (aged 9-14 years) from Turnverein Freiburg-Herdern.





Garrod Award Introduction — Lionel & Demian Martin

Two brothers, two instruments. Lionel and Demian Martin, aged 19 and 24, have reunited as a duo 3 years ago. In the meantime, Lionel Martin has become internationally known on the cello and has toured the world as a soloist with well-known orchestras and in a wide variety of chamber music ensembles, including a concert with Anne-Sophie Mutter.

The older brother Demian established himself as a piano cabaret artist and film music composer while studying piano. In sparkling unity they perform their repertoire, ranging from classical sonatas to modern character pieces, enriched by audience-requested improvisation encores.



Behind Human Understanding — Sophie Hauenherm

Introducing the session »Reality meets Metabolism« Sophie Hauenherm is going to present her choreography »Behind human understanding«. She created the dance as her Bachelor thesis at the end of her stage dance studies. Just six months before her finals, she developed an abscess in the region of the thoracic spinal cord and the doctors made the devastating diagnosis of an incomplete paraplegia. Instead of taking the diagnosis as it was, she was facing the challenge. She fought her way back to a life largely independent from the wheelchair. She would not accept her physical constraint and far more important she wouldn't let her dance be defined by it.

Today Sophie Hauenherm is proud of her way and tells her story through her dance. She wants to inspire and encourage other people with her way of dealing with her diagnosis and wants to build awareness.





Science Slam — Dr. Kai Hensel

Dr. Kai Hensel will present a science slam on the topic: The World of Epigenetics in the Scientific Theatre.

A science slam is an increasingly popular format of scientific communication in which the speakers present their research fields to a general (often non-expert) audience. Success is judged by the audience according to the educational content and, importantly, also the entertainment value. Recently, Dr. Hensel has mastered the genre winning multiple championships, finishing as runner-up for Germany (region West) and as national science slam championship finalist.

Dr. Hensel is a German born physician scientist who worked as a consultant in the Department of Pediatrics at Cambridge University Hospital before he moved to Göttingen, Germany. As from October 2022 he will be the Director of the Helios University Children's Hospital Wuppertal and Professor of Clinical Pediatrics at Witten/Herdecke University.

For his PhD he studied epigenetics of virus-host interactions in hepatitis B virus infection. His clinical research interests include advanced cardiovascular imaging techniques, health service sciences and digital healthcare innovations.

Dr. Hensel is also the creator and host of a new clinical pediatrics podcast (currently the most popular podcast on pediatric medicine in German language), called "Die Expertise-Piraten" - available at www.expertise-piraten.eu.

Scientific Theatre

1. Parallel to the poster walk, the 10 high-ranked posters will be presented in the Scientific Theatre.

Key facts

Where: Foyer
When: Wed, 31 August, 18:45 – 20:15 h
How: poster authors present their poster abstract
Who: all interested participants
.....

2. The patient group representatives will discuss with the audience the patients’ needs. A representative from Eurordis will also be present.

Key facts

Where: Foyer
When: Wed, 31 August, 13:00 – 13:45 h
Who: all interested participants
.....

3. Science Slam by Kai Hensel: The World of Epigenetics!

Key facts

Where: Foyer
When: Thu, 1 September, 12:45 - 13:00 h
Who: all interested participants
.....



Speed Mentoring

As a young professional in the field of metabolic medicine you will have the unique opportunity to speak one-on-one with advanced researchers and clinicians within and outside your speciality. During individual interviews of 7 minutes with up to 5 different mentors, you can get insider tips on how to develop a career plan, articulate career transitions and promotions, manage challenging situations at work and more. Bring your questions! This event will allow you to meet with different mentors in a protected professional environment.



Key facts

Where:	Meeting Room 1
When:	Tue, 30 August, 12:45 – 13:45 h Wed, 31 August, 07:30 – 08:30 h Thu, 1 September, 07:30 – 08:30 h Fri, 2 September, 07:30 – 08:30 h
How:	rolling system with different mentors
Who:	clinicians, scientists and laboratory specialists in training under the age of 35
Registration:	online, starting in August



Patient Organisations

The SSIEM symposium provides a platform for national and international patient organisations to connect with each other, discuss current challenges, and to join forces. The main topic of this side meeting is to identify «Patients’ needs”. After this meeting there will be an open discussion in the scientific theatre with every-one interested in the topic.



Key facts

- Where: London
- When: Wed, 31 August, 08:45 – 10:15 h
- How: meeting for patients and patient representatives, international networking, introduction lecture by EURORDIS representative Dr. Gulcin Gumus
- Who: patients and patient representatives
- Registration: patients and patient representatives, open to all interested participants

Alumni Café

For the first time, an Alumni Café will be held at the annual symposium to collect impressions, highlights and developments from the past 50 years. A place where we shed light on the history of the SSIEM as well as the trends in Metabolic Medicine. A place where old friends and colleagues meet again and share their memories in an informal and enjoyable atmosphere.



Key facts

- Where: Gallery Meeting Room 1
- When: Thu, 1 September, 12:30 – 14:00 h
- How: sharing memories of the last 50 years
- Who: retired and emerited colleagues and everybody who likes to connect with them

NETWORKING PROGRAMME

The main aim of our symposium is to share the latest research in the field of metabolic and genetic diseases – but of course it should also be a platform to socialise and network with old and new colleagues and friends.

Welcome Reception

Tue, 30 August, 18:30 – 21:00 h, Foyer

Finally – let us meet again in person for our scientific exchange at the SSIEM 2022! Networking is not least important and often is the motor for new research ideas. To initiate this year’s SSIEM symposium we welcome you to Freiburg with a special reception.


Kindly supported by 



Poster Walk

Wed, 31 August, 18:45 – 20:15 h, Messe Freiburg

At our Poster Walk you will have the chance to discuss the presented findings with the abstract authors. In parallel, the 10 highest ranked posters by young investigators will be presented in 7-minute contributions at our scientific theatre and there will be a floor for an open discussion.





Young SSIEM Evening

Wed, 31 August, 20:30 – 00:00 h, Freiburg City Centre

Young colleagues from all professions within the SSIEM (and of course those who like to connect with the young) are invited to better get to know each other and exchange ideas at this special Young SSIEM Evening. There is no age limit and everybody is welcome – but the idea of this special networking event is to strengthen the young SSIEM!

Registration: online – 15 EUR



Networking Evening

Thu, 1 September, 19:30 – 00:00 h, Konzerthaus Freiburg

Connect with participants from all over the world in a great atmosphere. We will bring the Black Forest into the heart of Freiburg and will give you a feeling of this special forest region in the southwest of Germany. It will be a special night and not at least a floor for personal exchange.

Registration: online – 30 EUR





GENERAL INFORMATION



Date

30 August – 2 September 2022

Website

www.ssiem2022.org



Symposium Venue

Messe Freiburg
Neuer Messplatz 1
79108 Freiburg, Germany



Symposium President

Prof. Dr. Ute Spiekerkötter
University Hospital of Freiburg
Freiburg, Germany



Congress Management

Intercongress GmbH
Alisa Ganter
Ingeborg-Krummer-Schroth-Str. 30
79106 Freiburg, Germany
ssiem@intercongress.de
www.intercongress.de



Exhibition Management and Sponsoring

Society for the Study of Inborn Errors
of Metabolism (SSIEM)
Ralph Kerschbaumer – Corporate Liaison Officer
PO Box 3375, South Croydon, CR2 1PN
United Kingdom
phone +43 512 890438
corporatelaisson@ssiem.org
www.ssiem.org

Symposium Office

Monday, 11:00 – 18:00 h

Tuesday, 07:30 – 18:30 h

Wednesday, 07:00 – 19:00 h

Thursday, 07:00 – 15:30 h

Friday, 07:00 – 13:00 h

Media Check for Speakers

Monday, 13:30 – 16:30 h

Tuesday, 07:30 – 19:00 h

Wednesday, 06:30 – 19:00 h

Thursday, 06:30 – 15:30 h

Friday, 07:30 – 13:00 h

WiFi Access

Network: SSIEM2022

Password: SSIEM2022



Kindly supported by

sanofi

CME Certification

An application has been made
to the UEMS EACCME®
for CME accreditation of this event.

Registration fees

SYMPOSIUM TICKET 4 DAYS	LATE REGISTRATION FROM 7 JULY 2022
SSIEM Member	550 EUR
Non-member	800 EUR
Students/Residents- in-Training (<35 yrs)	400 EUR
Dieticians & Nurses (reduced fee)	400 EUR

SINGLE DAY TICKET 1 DAY	LATE REGISTRATION FROM 7 JULY 2022
SSIEM Member	200 EUR
Non-member	300 EUR
Dieticians & Nurses (reduced fee)	200 EUR

Please register online at www.ssiem2022.org/registration

REGISTRATION FEE INCLUDES

Full Delegate (SSIEM Members, non-members, students & residents-in-training):

- Admission to all oral and poster sessions and exhibition area
- Scientific programme and symposium bag
- Access to the online version of the abstract book
- Coffee, tea and lunch bag during symposium breaks
- Welcome Reception
- Free public transport within Freiburg from 29 August to 2 September 2022

Networking Evening and Social Programme are to be paid for extra.

SINGLE DAY TICKET

- Admission to all oral and poster sessions and exhibition area
- Scientific programme and symposium bag
- Access to the online version of the abstract book
- Coffee, tea and lunch bag during symposium breaks of the day/ days of the ticket
- Free public transport within Freiburg on the day/ days of the ticket

Single day tickets do not allow access to social events. No more than two consecutive single day tickets can be purchased by one delegate.

Alterations & cancellation of congress registration

Written notification is required for all congress cancellations and name changes. Notifications should be sent to the SSIEM 2022 congress office **ssiem@intercongress.de**

For alterations of reservations or any other invoiced item an administrative fee of 20 EUR will be charged. A cancellation fee of 50 EUR will be charged for cancellations until 2 August 2022. The fee for congress participation will not be refunded, even in case of non-participation, if a cancellation is not received in time. A refused visa application is no reason for refund. Alternative participants are readily accepted for an administrative fee of 20 EUR. No reimbursement will be made in case of cancellation of a social programme from a participant. Please find full terms and conditions online at **www.ssiem2022.org/registration**

SSIEM

Become a member of SSIEM | To benefit from a reduced registration fee, apply to become a member of SSIEM today. Simply visit our website – www.ssiem.org – to see how.





SSIEM APP

GET THE SSIEM MOBILE APP!

- Access the scientific programme, networking programme, satellite symposia and faculty list
- Read the abstract texts
- Create your own daily schedule
- Visit partner and exhibitor profiles
- Stay informed and receive the latest news
- Chat with other attendees
- Post on our social feed

HOW TO DOWNLOAD:

The easiest way to download the mobile app is to scan this code. You can also search for **SSIEM** in the Apple Store or Google Play Store. Once you have installed the SSIEM app, you can access the SSIEM 2022 Congress by clicking on the top tile. After downloading the app, do not forget to enable push notifications to stay up-to-date on the latest news!



HOTEL

The Freiburg Convention Bureau has composed a list of many hotels in Freiburg, which you can find and book online at www.ssiem2022.org/hotel

For further information or group bookings please contact Kerstin Schultheis from Freiburg Convention Bureau via groups@fwtm.de or phone **+49 761 3881 1516**

TRAVEL


The Messe Freiburg is easily reachable whether you are traveling by air, car, train or bus.★


For more information about the best way to travel to Freiburg and for special rates please visit our website www.ssiem2022.org/travel

- ★ Your eTicket contains a free use of the extensive public transport system in Freiburg and the region from 29 August – 2 September 2022.



- Conference facilities
- Services
- Poster area
- Industry / exhibition area
- Meeting rooms







Mark Your Calendar!

SSIEM Annual Symposium 2023

29 August - 1 September 2023
Jerusalem, Israel



Important Dates & Deadlines

Start Online Registration: 4th January 2023

Start Call for Abstracts: 16th January 2023

Abstract Submission Deadline: 19th April 2023

ssiem2023.org



Freiburg

IM BREISGAU

Freiburg is located in the lower Rhine Valley between the mountain ranges of the Vosges and the Black Forest in the border-triangle of Germany, Switzerland and France. It is not only known as the »Green City« and »Solar City« of Germany, but is also the sunniest and warmest city in Germany. Freiburg was founded in the early 12th century. Nowadays, it has about 230,000 inhabitants. With its famous medieval old town, its modern buildings and its surrounding vineyards, unspoiled forests and rolling hills it combines urban lifestyle with environment in a special way like no other city.



Schwabentor © FWTM / Schoenen



Münstermarkt © FWTM / Schoenen



SPONSOR SECTION

PLATINUM



GOLD




SILVER



BRONZE



EXHIBITION AREA



EXHIBITORS

339 Aceragen

330 Aeglea BioTherapeutics

301 Ajinomoto Cambrooke

341 Alfasigma S.P.A.

316 Amicus Therapeutics

317 Amicus Therapeutics

323 APR Applied Pharma Research s.a.

322 ARCHIMEDlife/ amedes

327 Astellas Gene Therapies

314 Baebies

306 BioMarin

315 Bruker BioSpin

304 CENTOGENE

303 Chiesi Farmaceutici spa

334 CTI Clincial Trial & Consulting

336 Denali Therapeutics

319 Dipharma SA

340 Egetis Therapeutics

338 Galen

311 GC Biopharma co.

332 Immedica Pharma

325 JCR Pharmaceuticals

335 Labsystems Diagnostics

312 Lactalis Nutrition Sante

308 Lucane Pharma

329A membraPure GmbH

331 metaX Institut für Diätetik GmbH

324 Nutricia

302 Orchard Therapeutics (Europe) Limited

329 PassageBio

328 Piam Farmaceutici Spa

305 Prekulab Ltd. A/S

318 PTC Therapeutics

320 Recordati Rare Diseases

313 REGENXBIO Inc.

309 sanofi

310 sanofi

337 Sentyln Therapeutics

326 Takeda Pharmaceuticals International

307 Travere Therapeutics

333 Ultragenyx

321 Vitaflo International Ltd



SATELLITE SYMPOSIA & SPONSORING

INVITATION

SSIEM 2022 Satellite Symposia sponsored by BioMarin

Creating waves with PALYNZIQ® ▼ (pegvaliase): Three years of experience in Europe

Tuesday 30 August 2022 | 12:45-13:45 hrs, Hall Freiburg, Messe Freiburg, Germany

Moderator



Cary Harding, MD
Oregon Health & Science
University, Portland, OR, USA

Experience with PALYNZIQ® in the clinic



Ania Muntau, MD
University Children's Hospital,
University Medical Center
Hamburg-Eppendorf,
Hamburg, Germany



Valentina Rovelli, MD
ASST Santi Paolo e Carlo,
San Paolo Hospital,
University of Milan,
Milan, Italy

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Healthcare professionals should report adverse events in accordance with their local requirements. Adverse events should also be reported to BioMarin on +1 415 506 6179 or drugsafety@bmrn.com.


PALYNZIQ® Abbreviated
Prescribing Information



Improving the diagnostic pathway
in MPS and treating Morquio A in
the real world: best practice and
findings from MARS

Thursday 1 September 2022

12:45-13:45 hrs, Hall Freiburg, Messe Freiburg, Germany



Dr. Ekkehart Lausch University of Freiburg, Germany

Dr. Karolina Stepien Salford Royal Hospital, Manchester, UK

Prof. Fatih Ezgü Gazi University, Ankara, Turkey

BIO MARIN

These symposia have been initiated, organised and funded by BioMarin. These symposia are intended for healthcare professionals registered for SSIEM 2022 and will include information about licensed BioMarin products.

EU-MRL-00044
July 2022

| TUESDAY | 30 AUGUST 2022 | HALL FREIBURG | 12.45-13.45 |

**Creating waves with PALYNZIQ®▼ (pegvaliase):
Three years of experience in Europe**

Chair: Cary Harding, Portland, United States

Welcome & introduction: PALYNZIQ®▼ three years on

Cary Harding, Portland, United States

Riding the waves of change: My experience with PALYNZIQ®▼

Valentina Rovelli, Milan, Italy

My journey with PALYNZIQ®▼: A smooth sea does not make a skilled sailor

Ania Muntau, Hamburg, Germany

Q&A

Cary Harding, Portland, United States

sponsored by

B:OMARIN®

| NOTES |



| TUESDAY | 30 AUGUST 2022 | HALL JERUSALEM | 12.45-13.45 |

Optimization of long-term management of patients with organic acidaemia (propionic and methylmalonic acidurias)

Chairs: Sufin Yap, Sheffield, United Kingdom and Frank Rutsch, Münster, Germany

Introduction & Disease Overview

Sufin Yap, Sheffield, United Kingdom and Frank Rutsch, Münster, Germany

The metabolism and biochemistry we need to unravel Urea and Krebs Cycle interplay & impairment in PA & MMA

François Feillet, Nancy, France

Real-world evidence with Carbaglu®

The Prospective Observational study of long-TERM Carbaglu® for the Treatment of PA & MMA study (PROTECT study)

Understanding the long-term Management of Organic Acidemia Patients with Carbaglu®: A Mixed Methods Approach

Sufin Yap, Sheffield, United Kingdom

Long-term management & treatment of patients with propionic and methylmalonic acidurias with Carbaglu® — Experience in UK, France & Germany

Sufin Yap, Sheffield, United Kingdom,

François Feillet, Nancy, France,

Clemens Kamrath, Giessen, Germany

Three-year follow-up of patients with propionic and methylmalonic acidurias Long-term Carbaglu® vs liver transplant

Shirou Matsumoto, Kumamoto, Japan

Q & A and Closing Remarks

sponsored by



A Medscape **LIVE!** EVENT

CPD

Clinician and Patient Perspectives in the Management of Long-Chain Fatty Acid Oxidation Disorders

TUESDAY, 30 AUGUST, 2022 | 12:45 – 13:45 CET

REGISTRATION: 12:30 CET | **PRESENTATION:** 12:45 CET

MESSE FREIBURG, NEUER MESSPLATZ 1

79108 FREIBURG, GERMANY | **ROOM:** HALL PORTO



IN-PERSON EVENT

MODERATOR



Jerry Vockley, MD, PhD
Cleveland Family Endowed Chair in
Pediatric Research
Professor of Human Genetics
University of Pittsburgh
Chief of Genetic and Genomic Medicine
Director of the Center for
Rare Disease Therapy
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States

PANELISTS



Daniela Karall, MD, IBCLC
Professor of Pediatrics
Inherited Metabolic Disorders
Clinic for Pediatrics
Medical University of Innsbruck
Innsbruck, Austria



Stephanie Grünewald, MD, PhD
Consultant in Metabolic Medicine
Great Ormond Street Hospital for Children
NHS Foundation Trust
Senior Lecturer
Institute of Child Health
London, United Kingdom



For more information and to register, visit:

www.medscape.org/symposium/LC-FAOD-2022

Supported by an independent
educational grant from



Medscape
EDUCATION GLOBAL

| **TUESDAY** | **30 AUGUST 2022** | HALL PORTO | 12.45-13.45 |

**Clinician and Patient Perspectives in the Management
of Long-Chain Fatty Acid Oxidation Disorders**

Chair: Jerry Vockley, Pittsburgh, United States

Welcome and Introductions

Jerry Vockley, Pittsburgh, United States

Recognizing LC-FAODs Through Clinician and Patient Eyes

Stephanie Grünewald, London, United Kingdom

The Holistic Management of LC-FAOD: Combination Strategies

Daniela Karall, Innsbruck, Austria

Concluding Remarks

Jerry Vockley, Pittsburgh, United States

Audience Q&A

sponsored by





A RARE COMPANY

At Amicus Therapeutics, we strive to fulfill the bold commitment we've made to the rare disease community. This commitment keeps us at the forefront of developing therapies for those who need them most.



OUR COMMITMENT



As we pursue treatments for devastating rare diseases, we maintain a personal and compassionate focus on patients, their caregivers, and families.

OUR TECHNOLOGIES



We are leveraging our innovative technology platforms in protein stabilization and targeting to help advance treatments for human genetic diseases.

AT AMICUS THERAPEUTICS, WE ENCOURAGE AND EMBRACE **CONSTANT INNOVATION**



The FACES* of Fabry disease

*FACES: Fabry Associated Clinical Events – renal, cardiac and cerebrovascular outcomes

Welcome and introductions: Ana Jovanovic, Salford, United Kingdom

Patient perspectives: Experiences with FACES

- Two people living with Fabry disease share their experiences of FACES in a structured interview led by Ana Jovanovic
- Personal impact of FACES on the people living with Fabry disease and their families
People living with Fabry disease and Ana Jovanovic, Salford, United Kingdom

Session 1: Overview of FACES

Presentation of an overview of FACES, including:

- The multisystemic nature of Fabry disease and preclinical manifestations
- An introduction to FACES, including use as a treatment outcome (not just as a clinical trial tool) and impact on clinical management
- The effect of timely treatment in Fabry disease and the potential impact on FACES (including morbidity and mortality)
- Cardiac FACES – impact on QoL and correlation with other measures, based on clinical experience

Peter Nordbeck, Würzburg, Germany

Session 2: Incidence of FACES during migalastat treatment

Presentation of FACE incidence in patients receiving migalastat, including:

- Overview of previous data in the literature surrounding FACE incidence
- Incidence of FACES during a long-term post-hoc integrated analysis:
 - Overall incidence and incidence by event category (renal, cardiac and cerebrovascular)
 - Factors affecting time to first FACE
 - Association between baseline variables and rate of FACES (highlighting the importance of timely treatment initiation to manage disease)
- followME baseline data – comparative history of FACES and comorbidities across arms

Gere Sunder-Plassmann, Vienna, Austria

Live Q & A

Moderated by Ana Jovanovic with Peter Nordbeck and Gere Sunder-Plassmann

sponsored by





Satellite Symposia

Our enduring commitment to people
living with *rare diseases*

Come visit
us at our
booth

Satellite Symposia INVITATION

August 31st, 2022, 7:30 AM - 8:30 AM
Olipudase alfa: A New Treatment For Patients with ASMD

Chair: Dr. Eugen Mengel, MD SphinCS GmbH, Hochheim, Germany
Dr. Nathalie Guffon, MD Hôpital Femme Mère Enfant, Bron, France
Professor Maurizio Scarpa, MD, PhD Udine University Hospital, Udine, Italy

September 1st, 2022, 7:30 AM – 8:30 AM
Unmet Needs in Fabry Disease: Where To Go From Here?

Chair: Dr. Christoph Wanner, MD University Hospital of Würzburg, Germany
Dr. James Moon, MD, MRCP, MB BCH University College London and Barts Heart Centre- UK
Dr. Fatih Ezgü, MD Gazi University Hospital, Ankara, Turkey

September 1st, 2022, 12:45 PM-1:45 PM
Pompe Disease, A New Era: The Latest avalglucosidase alfa Clinical
Data and Early Real-World Experiences

Chair: Prof. Andreas Hahn, MD Department of Child Neurology, University Hospital - Giesen, Germany
Prof. Priya Kishnani, MD, MB BS Duke University School of medicine, Durham, North Carolina, USA
Dr. Serena Gasperini San Gerardo Hospital, University of Milano Bicocca, Italy

Sanofi-Aventis Deutschland GmbH - Lützowstraße 107
D-10785 Berlin – Germany
Approval Date: July 2022
MAT-GLB-2203155 v1.0

| **WEDNESDAY** | **31 AUGUST 2022** | HALL PORTO | 07.30-08.30 |

Olipudase alfa: a new treatment for patients with ASMD

Chair: Eugen Mengel, Hochheim, Germany

Welcome and introduction

Eugen Mengel, Hochheim, Germany

Sphingomyelin accumulation — Pathology behind the disease: sphingomyelin accumulation and clinical manifestations

Nathalie Guffon, Bron, France

Olipudase alfa data — Investigating olipudase alfa in clinical trials: efficacy and safety

Maurizio Scarpa, Udine, Italy

ASMD/olipudase alfa clinical case — The treatment outcome: an ASMD patient case study

Eugen Mengel, Hochheim, Germany

Panel discussion and Q & A

All panel

Closing remarks Eugen Mengel, Hochheim, Germany

sponsored by

sanofi



Classical Homocystinuria and Development of a New Enzyme Replacement Therapy

Wednesday, 31 August 2022, 07:30–08:30 CEST
SY6 Satellite Symposium, Kyoto meeting room

Breakfast will be provided



Traverse looks forward to welcoming you to a satellite symposium at SSIEM 2022.

We hope you can join our renowned experts **Dr Can Ficicioglu** and **Dr Andrew Morris** to discuss current and future management of classical homocystinuria (HCU)

Agenda

Welcome and Introduction

Can Ficicioglu & Andrew Morris

Overview of Classical HCU

Andrew Morris

Current Management of Classical HCU

Andrew Morris

Case Study: Patient Journey and Experience with Classical HCU

Can Ficicioglu

COMPOSE Phase 1/2 Trial: Overview of Interim Data on Pegtibatase

Can Ficicioglu

Your Questions Answered

Can Ficicioglu & Andrew Morris

Speakers

Can Ficicioglu MD, PhD

Professor of Pediatrics,
University of Pennsylvania, USA

Director, Newborn Screening &
Lysosomal Storage Disease Programs,
Children's Hospital of Philadelphia

Andrew Morris MBBS, MD, MRCP

Consultant Clinical Paediatrician in
Inherited Metabolic Medicine
University of Manchester, UK

This meeting is open to all registered delegates at the SSIEM 2022 congress.

© 2022 Traverse Therapeutics, Inc.
All rights reserved. July 2022 - MA-PE-22-0024

Classical Homocystinuria and Development of a New Enzyme Replacement Therapy

Welcome and Introduction

*Can Ficicioglu, Philadelphia, United States
Andrew Morris, Manchester, United Kingdom*

Overview of Classical HCU

Andrew Morris, Manchester, United Kingdom

Current Management of Classical HCU

Andrew Morris, Manchester, United Kingdom

Case Study: Patient Journey and Experience with Classical HCU

Can Ficicioglu, Philadelphia, United States

COMPOSE Phase 1/2 Trial: Overview of Interim Data on Pegtibatase

Can Ficicioglu, Philadelphia, United States

Your Questions Answered

*Can Ficicioglu, Philadelphia, United States
Andrew Morris, Manchester, United Kingdom*

sponsored by



**Reaching new highs in ex vivo gene therapy —
therapeutic advances for early onset MLD patients**

Chair: Simon Jones, Manchester, United Kingdom

Interactive panel discussion

MLD at a glance

Simon Jones, Manchester, United Kingdom

Libmeldy clinical data

Francesca Fumagalli, Milan, Italy

**Gene therapy treatment process — collaboration
between MLD and HSCT experts**

Caroline Sevin, Paris, France

Peter Van Hasselet, Utrecht, The Netherlands

MLD Newborn screening pilots in Europe

David Kasper, Vienna, Austria

sponsored by



| WEDNESDAY | 31 AUGUST 2022 | HALL PORTO | 18.45-20.15 |

Immunogenicity and Investigational AAV Gene Therapy

Chair: Benedikt Schoser, Munich, Germany

Welcome and Introductions

Benedikt Schoser, Munich, Germany

Immune Response: The Basics

Benedikt Schoser, Munich, Germany

Potential Immunogenic Responses to Investigational AAV Gene Therapy

Federico Mingozi, Spark Therapeutics, Inc., United States

Approaches Under Investigation that May Mitigate Immunogenicity in Investigational AAV Gene Therapy

Antonio Toscano, Messina, Italy

Live Panel Q & A

All faculty

sponsored by



SYMPOSIUM

Transformative science in action: Gene therapy for AADC deficiency

PTC Therapeutics symposium at the 15th SSIEM Annual Congress
1 September 2022, 07:30–08:30 CEST,
Hall Jerusalem, Messe Freiburg, Freiburg, Germany

Time (CEST)	Topic	Speaker
07:30–07:33	Welcome, introductions and objectives	Prof. Volker Mall
07:33–07:48	The eladocogene exuparvovec* clinical programme: The journey so far	Prof. Wuh-Liang Hwu
07:48–08:03	Navigating the AADC deficiency diagnostic journey from the caregiver’s perspective	Mr Richard Poulin and Mrs Judy Poulin
08:03–08:18	Real-world eladocogene exuparvovec treatment experience from Montpellier	Prof. Agathe Roubertie
08:18–08:28	Panel discussion	All faculty
08:28–08:30	Summary and close	Prof. Volker Mall

*Eladocogene exuparvovec is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype in the European Member States, Iceland, Liechtenstein, Norway, and Northern Ireland (Upstaza Summary of Product Characteristics [SmPC]).

AADC, aromatic L-amino acid decarboxylase; SSIEM, Society for the Study of Inborn Errors of Metabolism.



Symposium organised and funded by PTC Therapeutics
and intended for healthcare professionals only.

MED-ALL-AADC-2200166
July 2022

| **THURSDAY | 1 SEPTEMBER 2022** | HALL JERUSALEM | 07.30-08.30 |

**Transformative science in action:
Gene therapy for AADC deficiency**

Welcome, introductions and objectives

Volker Mall, Munich, Germany

The eladocogene exuparvovec clinical programme:

The journey so far

Wuh-Liang Hwu, Taipei, Taiwan

**Navigating the AADC deficiency diagnostic journey from
the caregiver's perspective**

Mr Richard Poulin and Mrs Judy Poulin

**Real-world eladocogene exuparvovec treatment experience
from Montpellier**

Agathe Roubertie, Montpellier, France

Panel discussion

All faculty

Summary and close

Volker Mall, Munich, Germany

sponsored by



| NOTES |



| THURSDAY | 1 SEPTEMBER 2022 | HALL PORTO | 07.30-08.30 |

Unmet Needs in Fabry disease: Where to go from here?

Chair: Christoph Wanner, Würzburg, Germany

Fabry Disease in 2022: How are we doing?

Christoph Wanner, Würzburg, Germany

Left Ventricular Involvement in Fabry Disease: Consequences and Assessment

James Moon, London, United Kingdom

Life with Fabry Disease: Impact of Pain and GI Disturbances

Fatih Ezgü, Ankara, Turkey

Discussion

Christoph Wanner, Würzburg, Germany

James Moon, London, United Kingdom

Fatih Ezgü, Ankara, Turkey

sponsored by

sanofi



Please join us at our symposium:

**Pompe Disease: A Metabolic
Disease Impacting Muscle and
Potential Muscle-directed
Gene Therapy Approaches**

**Challenges in the Diagnosis
of Pompe Disease**

Tahseen Mozaffar, MD, FAAN

University of California, Irvine
Irvine, California, USA

**Therapeutic Landscape for Pompe Disease
and Gene Therapy Approaches**

Benedikt Schoser, MD

Klinikum der Universität München,
Munich, Germany

Including Q&A

Thursday, Sept. 1 | 7:30-8:30

Kyoto Hall

To learn more, visit:

Booth #327

and

[AstellasGeneTherapies.com](https://www.astellasgenetherapies.com)



ASTELLAS and the flying star device are registered trademarks of Astellas Pharma Inc.

©2022 Audentes Therapeutics, Inc. All rights reserved.

DE-Pompe-072022-00001. July 2022.

| THURSDAY | 1 SEPTEMBER 2022 | HALL KYOTO | 07.30-08.30 |

Pompe Disease: A Metabolic Disease Impacting Muscle and Potential Muscle-directed Gene Therapeutic Approaches

Challenges in the Diagnosis of Pompe Disease

Tahseen Mozaffar, Orange, United States

Therapeutic Landscape for Pompe Disease and Gene Therapy Approaches

Benedikt Schoser, Munich, Germany

Q&A / Discussion

Moderated by Angela Smith, San Francisco, United States

sponsored by



Improving the diagnostic pathway in MPS and treating Morquio A in the real world: best practice and findings from MARS

Chair: Ekkehart Lausch, Freiburg, Germany

Welcome to the meeting

Ekkehart Lausch, Freiburg, Germany

Diagnostic challenges in MPS: can we reduce the diagnostic odyssey?

Fatih Ezgü, Ankara, Turkey

Long-term follow-up of Morquio A: 6-year data from the MARS registry

Karolina Stepień, Manchester, United Kingdom

Q & A panel discussion

Moderator: Ekkehart Lausch, Freiburg, Germany

Speakers: Karolina Stepień, Manchester, United Kingdom

Fatih Ezgü, Ankara, Turkey

Summary and meeting close

Ekkehart Lausch, Freiburg, Germany

sponsored by



**Pompe disease, a new era: the latest avalglucosidase
alfa clinical data and early real-world experiences**

Chair: Andreas Hahn, Giesen, Germany

Introduction by Chair

Andreas Hahn, Giesen, Germany

**COMET, Mini-COMET, and real-world evidence on avalglucosidase
alfa in the United States: What data do we have so far?**

Priya Kishnani, Durham, United States

Latest perspectives:

A case report of switching from alglucosidase alfa to avalglucosidase alfa

Serena Gasperini, Milan, Italy

**Looking to the future: Avalglucosidase alfa in infants
with Pompe disease (Baby-COMET) and impact of home
infusion therapy on quality of life**

Andreas Hahn, Giesen, Germany

Panel discussion and Q & A

Andreas Hahn, Giesen, Germany

Priya Kishnani, Durham, United States

Serena Gasperini, Milan, Italy

sponsored by


sanofi

SSIEM ANNUAL SYMPOSIUM

Optimizing early diagnosis in lysosomal storage diseases and innovation for the future

1 September 2022
12:45–13:45 CEST

A Takeda-sponsored satellite symposium at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2022 Annual Symposium



Chaired by Prof. Julia Hennermann, this 60-minute symposium aims to explore the innovative advancements for improving early diagnosis of lysosomal storage diseases (LSDs). During four presentations, our expert faculty will draw on their experience to highlight the importance of prompt diagnosis and to discuss thought-provoking developments in shortening the path to rare disease diagnosis through newborn genetic screening and digital technologies.

Presentations



The importance of early diagnosis in Fabry disease and potential innovative approaches

Prof. Julia Hennermann (Chair)
University Medical Center Mainz,
Mainz, Germany



Screen4Care: shortening the path to rare disease diagnosis using newborn genetic screening and digital technologies

Dr Edith (Sky) Gross
EURORDIS-Rare Diseases Europe,
Paris, France



Early diagnosis of leukodystrophies: recognizing key signs and symptoms

Prof. Ingeborg Krägeloh-Mann
University Children's Hospital Tübingen,
Tübingen, Germany



Newborn screening with a focus on mucopolysaccharidoses (MPS)

Prof. Shuan-Pei Lin
Mackay Memorial Hospital,
Taipei, Taiwan

This meeting is intended for healthcare professionals only and is initiated, organized and funded by Takeda.

Copyright 2022 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda logo are registered trademarks of Takeda Pharmaceutical Company Limited.

VV-MEDMAT-71248 Date of preparation: July 2022



**Optimizing early diagnosis in lysosomal storage diseases
and innovation for the future**

Chair: Julia Hennermann, Mainz, Germany

**The importance of early diagnosis in Fabry disease
and potential innovative approaches**

Julia Hennermann, Mainz, Germany

**Screen4Care: shortening the path to rare disease diagnosis
using newborn genetic screening and digital technologies**

Edith (Sky) Gross, Paris, France

**Early diagnosis of leukodystrophies: recognizing key signs
and symptoms**

Ingeborg Krägeloh-Mann, Tübingen, Germany

Newborn screening with a focus on mucopolysaccharidoses (MPS)

Shuan-Pei Lin, Taipei, Taiwan

sponsored by





Working to build
a brighter future
for patients



Date of preparation: June 2022 | ALL_22_141

| THURSDAY | 1 SEPTEMBER 2022 | HALL KYOTO | 12.45-13.45 |

What matters most?
Improving care in Lysosomal Storage Disorders (LSDs)

Chair: Maurizio Scarpa, Udine, Italy

Welcome and introductions

Maurizio Scarpa, Udine, Italy

Multidisciplinary care of patients with LSDs

Patricio Ricardo da Terra Aguiar, Lisbon, Portugal

Putting the Fabry disease patient at the heart of management

Uma Ramaswami, London, United Kingdom

**Alpha-mannosidosis: where can we make a difference
with Enzyme Replacement Therapy (ERT)?**

Nathalie Guffon, Lyon, France

20 years of ERT: learnings and aspirations

Maurizio Scarpa, Udine, Italy

Q&A

All faculty

sponsored by



[illegible]

HemoShear is dedicated to improving the lives of patients with rare diseases.

We are developing small molecule therapy HST5040 for the potential treatment of methylmalonic (MMA) and propionic acidemia (PA).



The **HERO** phase 2 clinical study of HST5040 is recruiting patients at select children's hospitals in the United States. More information can be found at clinicaltrials.gov (NCT04732429).

To learn more about HemoShear and be contacted about future studies, complete the form or reach out to Pat.Horn@Hemoshear.com.



HEMOSHEAR
THERAPEUTICS

10 Years of Rare Disease Diagnostics



Enzyme



Biomarker



Genetics

We are proud to have supported over 20,000 physicians in over 80 countries the last 10 years. Come celebrate with us and learn what we have planned for the next 10 years and beyond.

ARCHIMEDlife®



www.archimedlife.com

Booth

322

A part of the amedes Group

amedes 



SPECIALISTS FOR IEM

Looking forward to
meeting you at **booth 331**

DIETETIC FOODS

PKU/HPA	XPhe
TYR	ZeroTP
GLUT I	ZeroLys
MSUD	ZeroVIL
IVA	ZeroLeu
HOM	ZeroMet
MMA/PA	ZeroTVMI
UCD	plus8
PDE	SineLys
GSD	Glykogea



metax.org

Visit us
in booth
332

RAVICTI®
(glycerol phenylbutyrate) Oral Liquid
Rethink potential.

For the ongoing management of your UCD patients



In a long-term pooled analysis vs Sodium Phenylbutyrate (NaPBA), RAVICTI resulted in:

- Lower mean ammonia and glutamine levels leading to fewer decompensations¹
- Significant improvements in executive function in children¹

Reference: 1. Diaz GA, et al. Hepatology. 2013;57(6):2171–2179. Date of preparation: June 2022, COM-001843.

RAVICTI® 1.1 g/ml oral liquid Active ingredient: Glycerol phenylbutyrate. **Composition:** Each ml of the liquid contains 1.1 g glycerol phenylbutyrate (equivalent to a density of 1.1 g/ml). **Indications:** RAVICTI® is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome, HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI® must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). **Contraindications:** Hypersensitivity to the active substance. Treatment of acute hyperammonaemia. **Side effects: Common:** Decreased appetite, increased appetite, aversion to food, dizziness, headache, tremor, flatulence, diarrhoea, vomiting, nausea, abdominal pain, dyspepsia, abdominal distension, constipation, oral discomfort, retching, skin odour abnormal, acne, metrorrhagia, Fatigue, oedema peripheral, aspartate aminotransferase increased, alanine aminotransferase increased, anion gap increased, lymphocyte count decreased, vitamin D decreased. **Uncommon:** gastrointestinal viral infection, hypothyroidism, hypoalbuminaemia, hypokalaemia, dysgeusia, lethargy, paraesthesia, psychomotor hyperactivity, somnolence, Speech disorder, confusional state, depressed mood, ventricular arrhythmia, hot flushes, dysphonia, epistaxis, nasal congestion, oropharyngeal pain, throat irritation, abdominal discomfort, abnormal stool, dry mouth, belching, urgency to defecate, abdominal pain upper, abdominal pain lower, painful stool, steatorrhea, stomatitis, gallbladder pain, alopecia, hyperhidrosis, itchy rash, back pain, joint swelling, muscle spasms, pain in extremity, plantar fasciitis, bladder pain, amenorrhea, menstrual irregularity, hunger, pyrexia, increase in blood potassium, increase in blood triglycerides, abnormal electrocardiogram, Increase in low density lipoproteins, increase in prothrombin time, increase in white blood cell count, weight increase, weight decrease. Side effects that occur during long-term treatment with glycerol phenylbutyrate in paediatric than adult patients included upper abdominal pain (3 v. 49 paediatric [6.1%] vs. 1 v. 51 adult patients [2.0%]) and increased anion gap (2 v. 49 paediatric [4.1%] versus 0 v. 51 adult patients [0%]). **Permitted Owner:** Immedica Pharma AB - 113 29 Stockholm - Sweden. **Prescription only.** Email: info@immedica.com. Internet: www.immedica.com.

Immedica Pharma AB
Norrtullsgatan 15
113 29 Stockholm
Sweden

 **Immedica**
pharma



To discover more, please come and
see us at the Vitaflo stand.

We look forward to seeing you.



Enhancing Lives Together
A Nestlé Health Science Company

NUTRICIA
 PKU **Lophlex** Select

Your Way is the Best Way!

PKU Lophlex Select fits perfectly into your patients' lifestyle

Elegant, discreet and ready to drink with a unique range
 of flavours, and so low in calories!



LOW VOLUME

LOW CALORIE

CURIOUS TO LEARN MORE?

Come and visit the Nutricia Metabolics stand to be
 one of the first to experience our latest innovation!

PKU Lophlex Select® is a Food for Special Medical Purposes, must be used under medical supervision.
 For healthcare professionals only, not for distribution to the general public



INNOVATION FOR THE BETTER

We are an Italian pharmaceutical company committed to providing doctors and patients with products that derive from incremental innovation and technological formulation, independently of whether they are drugs, food supplements or food for special medical purposes.

We stand out as reference point for medical specialists and patients by developing and offering state-of-the-art solutions that help improve therapeutic compliance, especially in the rare and niche disease area, while still ensuring that patients have full access to the pharmaceutical and medical food options they need.

We work alongside the medical and scientific community and together with international partners who hold high technological expertise to identify and deliver the best therapeutic solutions more quickly.



Leading the
future of
rare disease
medicine

ultragenyx

Learn
about our
programs and
clinical trials

LC-FAOD: Long-Chain Fatty Acid Oxidation Disorders

HoFH: Homozygous Familial Hypercholesterolemia

OTCD: Ornithine Transcarbamylase Deficiency

GSDIa: Glycogen Storage Disease Type Ia

GSDIII: Glycogen Storage Disease Type III

MPSVII: Mucopolysaccharidosis VII

WD: Wilson Disease

Visit our booth at SSIEM

PKU GOLIKE

FEEL THE CHANGE



PKU GOLIKE is a food for special medical purposes for the dietary management of phenylketonuria. PKU GOLIKE Family is based on the patented **Physiomimic Technology™**, a unique formulation that provides a **physiological absorption of amino acids** in line with natural proteins.

PKU GOLIKE Plus

Granules to be mixed with warm/cold food and drinks or with **GOLIKE Shake & Drink**.

PKU GOLIKE KRUNCH

Practical **tablets** to be chewed. *Anywhere, anytime!*

PKU GOLIKE BAR

COMING SOON!

Delicious **fruit bars** with amino acid mix to snack.

PKU GOLIKE products must be used under medical supervision.



Visit our booth
and immerse yourself
in a **3D experience!**



Delivering Metabolic Harmony. Transforming Life.

Aeglea specializes in rare metabolic disorders, developing novel medicines to bring better balance to the lives of patients and families battling these devastating diseases.



Program	Research	Phase 1/2	Phase 3	Approved
Pegzilarginase Arginase 1 Deficiency	<div></div>	<div></div>		
AGLE-177 Homocystinuria	<div></div>	<div></div>		
AGLE-325 Cystinuria	<div></div>	<div></div>		
Undisclosed Rare Diseases	<div></div>	<div></div>		



©2022 Aeglea BioTherapeutics.
All rights reserved.
US-ARG-200081 06/22
aeglea.com

aeglea™

CENTOGENE

Multiomic Solutions

Empower Us to Go Beyond Diagnostics.

Meet Us at
Booth #304





*Better Together.
Improved Solutions for Rare Diseases.*

Dipharma S.A. is a Swiss pharmaceutical company specialized in developing high quality, improved generic medicines for rare metabolic diseases.



www.dipharma.ch

-  Worldwide distribution through a network of selected national partners
-  Marketing in Germany through the affiliate

 **Dipharma**
Arzneimittel



*"Our mission is to simplify the treatment relationship
between doctors and their patients"*

Visit us at Booth #308
to learn more about Lucane Pharma and its
products for Urea Cycle Disorders

We look forward to
meeting you in **Freiburg!**

www.lucanepharma.com

PH000003-2-1-09-2022-02 Lucane Pharma (Netherlands) B.V. Lucane Pharma (Netherlands) B.V. Lucane Pharma (Netherlands) B.V. Lucane Pharma (Netherlands) B.V. Lucane Pharma (Netherlands) B.V.



Take control of PKU

PrekulaB's innovative range of tablets and powders allows patients to live a more ordinary life with phenylketonuria.

Our range includes the pioneering LNAA products PreKUnil and NeoPhe, which provide brain protection, lower blood Phe level and allow an up to 80% regular diet, and trusted AA product Avonil with well-proven performance over 30 years.

PrekulaB offers various and convenient packaging solutions including sachets.

Find out more at www.prekulab.com

PreKUnil NeoPhe Avonil

**Visit us at
booth 305**



Mark Your Calendar!

SSIEM Annual Symposium 2023

29 August - 1 September 2023
Jerusalem, Israel

החברה הישראלית
למחלות מטבוליות
Israel Society for
Metabolic Diseases



Important Dates & Deadlines

Start Online Registration: 4th January 2023

Start Call for Abstracts: 16th January 2023

Abstract Submission Deadline: 19th April 2023

| NOTES |





We chase the *miracles of science*,
with an enduring commitment to
better care for rare.

We strive to:

- Break down the barriers to timely and accurate rare disease diagnoses
- Discover and develop new, innovative treatments that improve real-world outcomes
- Advocate for equitable access to medicines
- Elevate the voices of people living with rare diseases and support them across their lifelong journey

Come visit us at our booth



James
ASMD
United Kingdom

Sanofi-Aventis Deutschland GmbH - Lützowstraße 107
D-10785 Berlin – Germany
Approval Date: July 2022
MAT-GLB-2203149 v1.0